Patent Publication Number: US-2020276298-A1

Title: Paramyxoviridae expression system

Description:
BACKGROUND OF THE INVENTION 
     A. Field of the Invention 
     The present invention relates to the field of (vector) vaccines, and especially to an enhanced arrangement of nucleotide sequences for expressing an exogenous gene of interest by means of a Paramyxoviridae virus containing said exogenous gene. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine. 
     B. Background and Description of the Related Art 
     Paramyxoviruses of the Paramyxoviridae family are negative-sense, single-stranded, RNA viruses that are responsible for many prevalent animal and human diseases. Examples of paramyxoviruses are Newcastle disease virus infecting poultry and other avian species or measles virus causing disease in human beings. These viruses currently comprise 49 species, which are divided into 7 genera, among them the genus Morbillivirus with seven species. 
     Canine distemper (CD) is a highly infectious, febrile disease of dogs and other. The mortality rate is high, ranging between 30 and 80 percent. Dogs surviving CD often have permanent central nerve system damage. The established etiology of CD is infection by a member of the Paramyxoviridae family, Morbillivirus genus known as CD virus (CDV). In general, Paramyxoviruses are enveloped viruses containing an 18-20 kb single stranded RNA genome of negative polarity. The genome encodes 5 to 7 structural proteins including a fusion (F) and either a hemagglutinin-neuraminidase (HN) or hemagglutinin (H) glycoprotein. The membrane glycoprotein hemagglutinin (H) is responsible for attachment of the virus to the host cell, and the fusion glycoprotein (F) causes membrane fusion between the virus and the infected cell or between the infected and adjacent uninfected cells. 
     The genome termini of members of Paramyxoviridae consist of extragenic regions, called the 3′-leader and 5′-trailer: the 3′-leader region contains the genome promoter, and the trailer encodes the 3′ end of the antigenome, which is the full-length positive-sense replicative intermediate, which contains the antigenome promoter. Each gene starts with a conserved gene start (GS) sequence and ends with a conserved gene end (GE) sequence. Transcription begins at the 3′-leader region and proceeds in a sequential manner by a start-stop mechanism by which the individual genes are transcribed into individual, separate mRNAs. The genes are separated by non-coding intergenic sequences (IGS) that are conserved in length and sequence among the different gene junctions for some genera (Respirovirus, Morbillivirus, and Henipavirus) and are non-conserved in sequence or length for others (Rubulavirus, Avulavirus, Pneumovirus, and Metapneumovirus). 
     For CDV, both F and H glycoproteins are found present in the viral envelope and on the surface of infected cells. By inference from analyses with other Morbillivirus members, the CDV F and H glycoproteins appear important and are essential for CDV infection and its immunobiology. Poxvirus based recombinant CDV vaccines have been developed to protect and treat dogs (U.S. Pat. No. 5,756,102). US patent application U.S. Ser. No. 09/587,964 disclosed DNA plasmid based vaccines expressing CDV antigens. 
     Wang et al. (Vaccine 30: 5067-5072 (2012)) have generated a recombinant CDV vaccine strain expressing the rabies virus glycoprotein by using reverse genetics. 
     However, a disadvantage seen in practice is that such a virus strain, presumably mediated by homologous recombination between duplicated non-coding region sequence(s), may lose the inserted gene over time. 
     Thus, there is a strong need for an expression system which allows to stably insert a foreign gene into a Paramyxoviridiae virus genome. 
     Furthermore, canine distemper virus and canine parvovirus (CPV) are two major pathogens of canids and other carnivores with a global distribution. The epidemiology of these two viruses in carnivore populations and their successful control are highly dependent on active immunization of susceptible hosts. The vaccination schemes most often comprise the usage of polyvalent vaccines containing among others attenuated live canine parvovirus and canine distemper components. However, the successful immunization is dependent on the age category, previous immune status and the presence of maternally derived immunity. There is a strong need to find improved vaccines protecting against major pathogens of canids such as canine distemper virus and canine parvovirus. 
     SUMMARY OF THE INVENTION 
     The solution to the above technical problem(s) is achieved by the description and the embodiments characterized in the claims. 
     Thus, the invention in its different aspects is implemented according to the claims. 
     The invention is based on the surprising finding that the insertion of an expression cassette, comprising a foreign gene flanked at the 5′ end by a 5′ non-coding region of a nucleoprotein (N) gene of a CDV virus, between the phosphoprotein (P) gene and the matrix protein (M) gene of a CDV virus genome (see  FIG. 1 ), creates a virus vector allowing to accommodate, maintain and express the foreign gene even over long periods of time. This allows the generation of genetically stable transgene Paramyxoviridae based vectors such as CDV based vectors. 
     In a first aspect, the invention thus provides an expression cassette for insertion between two adjacent essential genes (1; 2) of a Paramyxoviridae virus such that the first gene (1) is located in 3′ direction and the second gene (2) is located in 5′ direction of the expression cassette, wherein said expression cassette comprises
         a first nucleotide sequence, wherein said first nucleotide sequence is a nucleotide sequence of interest, and   a second nucleotide sequence flanking the 5′ end of the first nucleotide sequence, wherein said second nucleotide sequence is the 5′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the first gene (1).       

     The expression cassette of the present invention is preferably an RNA molecule. Preferably, said expression cassette is an isolated expression cassette. 
     The expression cassette according to the invention preferably further comprises
         a third nucleotide sequence flanking the 3′ end of the first nucleotide sequence, wherein said third nucleotide sequence comprises or consists of the 3′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2).       

     In a specific aspect, the present invention uses the Lederle vaccine strain of CDV (deposited at the ATCC under the accession number VR-128) as a backbone (genotype represented by GenBank Accession DQ903854.1, AY288311 or AY286480) or an at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical sequence thereof, such as from virus derived by additional passages thereof (e.g. Canine Distemper Virus, Lederle Avirulent, Catalog No. NR-3845, Biodefense and Emerging Infections Research Resources Repository, P.O. Box 4137, Manassas, Va. 20108-4137, USA). 
     The plasmid map in  FIG. 2  exemplarily shows a DNA construct to generate a vector according to the invention. 
     The vector according to the invention is in particular useful for the vaccination of mammals, in particular of swine. 
     The present invention further concerns a vector for dual immunization against CDV and another virus, especially CDV and another canine virus such as CPV. This dual immunization vector expresses CDV antigens from the vector backbone and other canine antigens such as CPV VP2, which are inserted as transgene. 
     The invention thus also provides a canine distemper virus (CDV) vector comprising a heterologous RNA sequence of interest, which is preferably located between a P gene and an M gene of a CDV, and wherein said heterologous RNA sequence of interest encodes a Canine Parvovirus (CPV) VP2 protein. 
     Furthermore, the present invention contemplates vectors for inducing an immune response against swine influenza virus or porcine epidemic diarrhea virus in pigs, Thus, in the context of the present invention also Paramyxoviridae virus vectors are provided comprising an expression cassette with a heterologous RNA sequence, which encodes H3-subtype hemagglutinin of swine influenza virus or a Spike protein of porcine epidemic diarrhea virus. 
     The present invention further concerns mammalian host cells comprising such vectors and methods of generating vector vaccines using such host cells, as well as immunogenic compositions and vaccines comprising the CDV vector of the present invention. 
     DETAILED DESCRIPTION OF THE INVENTION 
     The present invention solves the problems inherent in the prior art and provides a distinct advance in the state of the art. 
     The present invention shows by in vitro data the investigation of CDV recombinants created in accordance with the teaching provided herein (i.e., CDV vectors) encoding VP2 proteins from either 2b or 2c CPV genotypes. The viruses showed good growth kinetics on production in Vero cells, reaching peak titres at 6 days post infection in roller bottles. The recombinants showed strong expression characteristics of transgenes (VP2) as determined by immunofluorescence and Western Blot, which qualifies them as dual CDV-CPV vaccine candidates. In addition, such viruses were tested for genetic stability for 20 cell passages on Vero cells. Both viruses remained fully genetically stable, indicating that they are susceptible for vaccine bio-processing. 
     The present invention further demonstrates by in vivo results that CDV vector according to the invention replicated in swine host, targeting lymphatic cells. By sampling and testing the various organs, the virus was detected in lymph nodes, spleen or tonsils of vaccinated animals. Importantly, all sentinel animals remained sero-negative until the end of the study, indicating that the recombinant CDV viruses were not spread from animal to animal upon vaccination. 
     Concerning the efficacy, all animals vaccinated with CDV-VP2 seroconverted against canine parvovirus 2 (as measured by CPV-virus neutralization test). Particular increase in neutralizing antibody titres was detected after the 2 nd  vaccination (see  FIG. 6 ). The levels of neutralizing antibodies at 21 days after second immunization reached the levels of 1:40 to 1:400, which according to the literature, represents a protective titre range in a real host (canids) (Glover et al. 2012, Taguchi et al. 2011). 
     Furthermore, the use of a CDV vector according to the invention encoding H3-subtype hemagglutinin (H3) of swine influenza virus lead to the development of active immunity in H3N2-Maternally Derived Antibody-positive (H3N2-MDA-positive) piglets despite the presence of such passively present maternal immunity. 
     Further, a CDV vector according to the invention encoding Spike protein of porcine epidemic diarrhea virus (PEDV) was intranasally administered to sows, which then resulted, through antibody positive colostrum intake, in passive immunization of piglets seen by a reduced incidence or severity of the clinical signs, letality and virus shedding after a challenge with PEDV. 
     Generally, the present invention provides an expression cassette, which is also termed “the expression cassette of the present invention” hereinafter, for insertion between two adjacent essential genes (1; 2) of a Paramyxoviridae virus such that the first gene (1) is located in 3′ direction and the second gene (2) is located in 5′ direction of the expression cassette, wherein said expression cassette comprises
         a first nucleotide sequence, wherein said first nucleotide sequence is a nucleotide sequence of interest, and   a second nucleotide sequence flanking the 5′ end of the first nucleotide sequence, wherein said second nucleotide sequence is the 5′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the first gene (1), and   a third nucleotide sequence flanking the 3′ end of the first nucleotide sequence, wherein said third nucleotide sequence comprises or consists of the 3′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2).       

     Preferably, said third nucleotide sequence consists of
         the 3′ non-coding region of a gene selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2), and   a sequence flanking the 5′ end of said 3′ non-coding region, wherein said sequence flanking the 5′ end of said 3′ non-coding region encodes a consensus sequence for initiation or enhancing of translation, and wherein said consensus sequence for initiation or enhancing of translation is optionally a Kozak sequence.       

     According to another preferred aspect, the expression cassette of the present invention consists of
         said first to third nucleotide sequences, and   a further nucleotide sequence flanking the 5′ end of the second nucleotide sequence or flanking the 3′ end of said third nucleotide sequence, wherein said further nucleotide sequence is an intergenic sequence of a Paramyxoviridae virus.       

     Said two adjacent genes (1; 2) of a Paramyxoviridae virus are preferably selected from the group consisting of the essential genes of a Paramyxoviridae virus, and/or said essential genes of a Paramyxoviridae virus are the N, P, M, F, H and L gene of a Paramyxoviridae virus, or the N, P, M, F, HN and L gene of a Paramyxoviridae virus, or the N, P, M, F, G, and L gene of a Paramyxoviridae virus. 
     According to one exemplary embodiment, the invention provides an expression cassette for insertion between the P gene and the M gene of a Paramyxoviridae virus, wherein
         said group consisting of the essential genes of a Paramyxoviridae virus excluding the first gene (1) is the group consisting of the essential genes of a Paramyxoviridae virus excluding the P gene of a Paramyxoviridae virus, and wherein said gene is optionally selected from the group consisting of the N, M, F, H and L gene of a Paramyxoviridae virus, and   said group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2) is the group consisting of the essential genes of a Paramyxoviridae virus excluding the M gene of a Paramyxoviridae virus, and wherein said gene is optionally selected from the group consisting of the H, P, F, L and N gene of a Paramyxoviridae virus.       

     Preferably, said second nucleotide sequence is the 5′ non-coding region of a gene selected from the essential genes of a Paramyxoviridae virus located in 3′ direction of the expression cassette, excluding the 5′ non-coding region of the first gene (1), and/or 
     said third nucleotide sequence comprises or consists of the 3′ non-coding region of an essential gene of a Paramyxoviridae virus located in 5′ direction of the expression cassette, excluding the 3′ non-coding region of the second gene (2). 
     According to another preferred aspect, said first nucleotide sequence of the expression cassette of the present invention is operably linked to the gene start (GS) sequence included in said third nucleotide sequence and/or to the genome promoter of a Paramyxoviridae virus. 
     Said first to third nucleotide sequences and said further nucleotide sequence of the expression cassette of the present invention are preferably RNA sequences, such that said first nucleotide sequence is then a first RNA sequence, said second nucleotide sequence is a second RNA sequence, said third nucleotide sequence is a third RNA sequence, and said further nucleotide sequence is a further RNA sequence. 
     In one example, the expression cassette of the present invention comprises
         a first RNA sequence, wherein said first RNA sequence is an RNA sequence of interest, and   a second RNA sequence flanking the 5′ end of the first RNA sequence, wherein said second RNA sequence is the 5′ non-coding region of an N gene of a Paramyxoviridae virus, and   a third RNA sequence flanking the 3′ end of the first RNA sequence, wherein said third RNA sequence consists of   the 3′ non-coding region of a gene selected from the group consisting of hemagglutin (H) gene of a Paramyxoviridae virus, phosphoprotein (P) gene of a Paramyxoviridae virus, fusion protein (F) gene of a Paramyxoviridae virus, large polymerase protein (L) gene of a Paramyxoviridae virus, and nucleoprotein (N) gene of a Paramyxoviridae virus, and   a sequence flanking the 5′ end of said 3′ non-coding region, wherein said sequence flanking the 5′ end of said 3′ non-coding region encodes a Kozak sequence, and   optionally a further RNA sequence flanking the 5′ end of the second nucleotide sequence or flanking the 3′ end of said third nucleotide sequence, wherein said further nucleotide sequence is an intergenic sequence of a Paramyxoviridae virus.       

     For purposes of illustration, a schematic representation of an arrangement of RNA sequences as described herein, in connection with exemplary specific sequences provided hereinafter, is given in  FIG. 3 . 
     Preferably, the expression cassette of the present invention is non-naturally occurring and/or is included in the genome of an isolated Paramyxoviridae virus vector. 
     The Paramyxoviridae virus, as mentioned herein, is particularly a virus of the genus Morbillivirus, and wherein the virus of the genus Morbillivirus is preferably selected from the group consisting of canine distemper virus (CDV), feline morbillivirus (FeMV), and peste-des-petits-ruminants virus (PPRV), and wherein the virus of the genus Morbillivirus is most preferably a canine distemper virus (CDV). For instance, in the case that a CDV is chosen as the Paramyxoviridae virus, then the Paramyxoviridae virus vector described hereinafter is in particular a CDV vector. 
     According to a another aspect, the present invention furthermore relates to a Paramyxoviridae virus vector, comprising the expression cassette of the present invention, and wherein said Paramyxoviridae virus vector is also termed “the Paramyxoviridae virus vector of the present invention” herein. The Paramyxoviridae virus vector of the present invention is preferably an isolated Paramyxoviridae virus vector. 
     In one preferred aspect, the invention relates to said Paramyxoviridae virus vector or to the expression cassette of the present invention, wherein
         said 5′ non-coding region is the 5′ non-coding region of an N gene of a Paramyxoviridae virus, and/or   said 3′ non-coding region is the 3′ non-coding region of an H gene of a Paramyxoviridae virus,
 
and/or wherein said expression cassette is inserted between a P gene and an M gene of a Paramyxoviridae virus.
       

     Thus, the invention also relates to a Paramyxoviridae virus vector comprising an RNA sequence inserted between two adjacent essential genes (1; 2) of a Paramyxoviridae virus such that the first gene (1) is located in 3′ direction and the second gene (2) is located in 5′ direction of said inserted RNA sequence, and wherein said inserted RNA sequence comprises or consists of
         a first RNA sequence, wherein said first RNA sequence is a nucleotide sequence of interest, and   a second RNA sequence flanking the 5′ end of the first RNA sequence, wherein said second RNA sequence is the 5′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the first gene (1), and   a third RNA sequence flanking the 3′ end of the first RNA sequence, wherein said third RNA sequence comprises or consists of the 3′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2).       

     Preferably, said first RNA sequence is operably linked to the gene start (GS) sequence included in said third RNA sequence and/or to the genome promoter of a Paramyxoviridae virus. 
     In accordance with a particular preferred aspect, said two adjacent genes (1; 2) of a Paramyxoviridae virus are selected from the group consisting of the essential genes of a Paramyxoviridae virus 
     and/or said essential genes of a Paramyxoviridae virus are
         the N, P, M, F, H and L gene of a Paramyxoviridae virus, or   the N, P, M, F, HN and L gene of a Paramyxoviridae virus, or   the N, P, M, F, G, and L gene of a Paramyxoviridae virus.       

     According to a further preferred aspect, said third RNA sequence of the Paramyxoviridae virus vector of the present invention consists of
         the 3′ non-coding region of a gene selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2), and   a sequence flanking the 5′ end of said 3′ non-coding region, wherein said sequence flanking the 5′ end of said 3′ non-coding region encodes a consensus sequence for initiation or enhancing of translation, and wherein said consensus sequence for initiation or enhancing of translation is optionally a Kozak sequence.       

     In one example, wherein said two adjacent essential genes (1; 2) of a Paramyxoviridae virus are the P gene and the M gene of a Paramyxoviridae virus, then
         said group consisting of the essential genes of a Paramyxoviridae virus excluding the first gene (1) is the group consisting of the essential genes of a Paramyxoviridae virus excluding the P gene of a Paramyxoviridae virus, and wherein said gene is optionally selected from the group consisting of the N, M, F, H and L gene of a Paramyxoviridae virus, and   said group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2) is the group consisting of the essential genes of a Paramyxoviridae virus excluding the M gene of a Paramyxoviridae virus, and wherein said gene is optionally selected from the group consisting of the H, P, F, L and N gene of a Paramyxoviridae virus.       

     In the context of the Paramyxoviridae virus vector of the present invention, preferably
         said second nucleotide sequence is the 5′ non-coding region of a gene, wherein the gene is selected from the essential genes of a Paramyxoviridae virus located in 3′ direction of the expression cassette excluding the first gene (1), which in particular means that the 5′ non-coding region of the first gene (1) is not selected, respectively, and/or   said third nucleotide sequence comprises or consists of the 3′ non-coding region of a gene, wherein the gene is selected from the essential genes of a Paramyxoviridae located in 5′ direction of the expression cassette excluding the second gene (2), which in particular means that the 3′ non-coding region of the second gene (2) is not selected, respectively.       

     It is furthermore preferred, regarding the Paramyxoviridae virus vector of the present invention, that
         said 5′ non-coding region is a 5′ non-coding region of an N gene of a Paramyxoviridae virus, and/or   said 3′ non-coding region is a 3′ non-coding region of an H gene of a Paramyxoviridae virus.       

     Preferably, the expression cassette or the Paramyxoviridae virus vector of the present invention in particular comprises
         a first RNA sequence, wherein said first RNA sequence is an RNA sequence of interest, and   a second RNA sequence flanking the 5′ end of the first RNA sequence, wherein said second RNA sequence is the 5′ non-coding region of a nucleoprotein (N) gene of a Paramyxoviridae virus, and   a third RNA sequence flanking the 3′ end of the first RNA sequence, wherein said third RNA sequence consists of
           the 3′ non-coding region of a H, HN, F, or L gene of a Paramyxoviridae virus, and   a sequence flanking the 5′ end of said 3′ non-coding region, wherein said sequence flanking the 5′ end of said 3′ non-coding region encodes a Kozak sequence.   
               

     According to a another preferred aspect, the Paramyxoviridae virus vector of the present invention further comprises
         a fourth RNA sequence flanking the 5′ end of the second RNA sequence, wherein said fourth RNA sequence is an intergenic sequence of a Paramyxoviridae virus, and/or   a fifth RNA sequence flanking the 3′ end of the fourth RNA sequence, wherein said fifth RNA sequence is an intergenic sequence of a Paramyxoviridae virus.       

     Preferably, said third RNA sequence of the expression cassette of the present invention or of the Paramyxoviridae virus vector of the present invention comprises or consists of a 3′ non-coding region of an H gene of a Paramyxoviridae virus and/or said expression cassette is preferably inserted between a P gene and an M gene of a Paramyxoviridae virus. 
     According to a particularly preferred aspect, the invention also relates to 
     (A) an expression cassette of the present invention comprising
         a first RNA sequence, wherein said first RNA sequence is a heterologous or exogenous RNA sequence of interest, and   a second RNA sequence flanking the 5′ end of the first RNA sequence, wherein said second RNA sequence is the 5′ non-coding region of an N gene of a CDV, and   a third RNA sequence flanking the 3′ end of the first RNA sequence, wherein said third RNA sequence consists of
           the 3′ non-coding region of a H, HN, F, or L gene of a Paramyxoviridae virus, and   a sequence flanking the 5′ end of said 3′ non-coding region, wherein said sequence flanking the 5′ end of said 3′ non-coding region encodes a Kozak sequence,   
           and wherein said expression cassette preferably further comprises   a fourth RNA sequence flanking the 5′ end of the second RNA sequence, wherein said fourth RNA sequence is an intergenic sequence of a CDV, or   a fifth RNA sequence flanking the 3′ end of the third RNA sequence, wherein said fifth RNA sequence is an intergenic sequence of a CDV, and, respectively, the invention also relates to
 
(B) a Paramyxoviridae virus vector of the present invention comprising the expression cassette of (A), wherein this vector is also termed “CDV vector of the present invention” herein.
       

     Preferably, said first nucleic acid sequence of the expression cassette of the present invention or of the Paramyxoviridae virus vector of the present invention is operably linked to the gene start (GS) sequence included in said third RNA sequence and/or to the genome promoter of a Paramyxoviridae virus. 
     In the context of the expression cassette of the present invention or the Paramyxoviridae virus vector of the present invention, said Paramyxoviridae virus is preferably a CDV and said 5′ non-coding region of a gene of a CDV is selected from the group consisting of 
     the 5′ non-coding region of an N gene of a CDV, wherein the 5′ non-coding region of an N gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:1,
 
the 5′ non-coding region of a P gene of a CDV, wherein the 5′ non-coding region of a P gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:2,
 
the 5′ non-coding region of an M gene of a CDV, wherein the 5′ non-coding region of an M gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:3,
 
the 5′ non-coding region of an F gene of a CDV, wherein the 5′ non-coding region of an F gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:4,
 
the 5′ non-coding region of an H gene of a CDV, wherein the 5′ non-coding region of an H gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:5, and
 
the 5′ non-coding region of an L gene of a CDV, wherein the 5′ non-coding region of an L gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:6.
 
     Within the context of the expression cassette of the present invention or the Paramyxoviridae virus vector of the present invention, said Paramyxoviridae virus is preferably a CDV and said 3′ non-coding region of a gene of a CDV is selected from the group consisting of 
     the 3′ non-coding region of an H gene of a CDV, wherein the 3′ non-coding region of an H gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:7,
 
the 3′ non-coding region of an N gene of a CDV, wherein the 3′ non-coding region of an N gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:8,
 
the 3′ non-coding region of a P gene of a CDV, wherein the 3′ non-coding region of a P gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:9,
 
the 3′ non-coding region of an M gene of a CDV, wherein the 3′ non-coding region of an M gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:10,
 
the 3′ non-coding region of an F gene of a CDV, wherein the 3′ non-coding region of an F gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:11, and
 
the 3′ non-coding region of an L gene of a CDV, wherein the 3′ non-coding region of an L gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:12.
 
     Preferably, said second nucleotide sequence or said second RNA sequence of the expression cassette of the present invention or of the Paramyxoviridae virus vector of the present invention is the 5′ non-coding region of an N gene of a CDV, and wherein said 5′ non-coding region of an N gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:1. 
     Regarding the expression cassette of the present invention or the Paramyxoviridae virus vector of the present invention, preferably
         said 3′ non-coding region of a gene selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2) is the 3′ non-coding region of an H gene of a CDV, and wherein said 3′ non-coding region of an H gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:7, and/or   said sequence flanking the 5′ end of said 3′ non-coding region sequence encodes a Kozak sequence being 5 to 8 nucleotides in length, and wherein the Kozak sequence preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:13.       

     Preferably, said intergenic sequence of the expression cassette of the present invention or of the Paramyxoviridae virus vector of the present invention is an intergenic sequence of a CDV, and wherein said intergenic sequence of a CDV preferably consists of or comprises an RNA sequence being at least 66% identical with the sequence of SEQ ID NO:14. 
     Preferably, said nucleotide sequence of interest, as described herein in the context of the expression cassette of the present invention or of the Paramyxoviridae virus vector of the present invention, is a gene of interest or an antigen encoding sequence, and/or said nucleotide sequence of interest is preferably non-naturally occurring and/or recombinant. 
     In particular, said nucleotide sequence of interest is preferably recombinant and/or heterologous and/or exogenous. 
     Said nucleotide sequence of interest preferably encodes an antigen from a disease-causing agent, wherein the disease-causing agent is preferably a disease-causing agent capable of infecting a companion animal, such as a canine or feline and/or any other domestic or wild carnivore, or capable of infecting a food producing animal such as swine or cattle. 
     According to one preferred aspect of the present invention, the Paramyxoviridae virus is a Paramyxoviridae virus capable of infecting an animal of a first biological family and the nucleotide sequence of interest encodes an antigen from a disease-causing agent capable of infecting an animal of said first biological family, and wherein said disease-causing agent is preferably different from said Paramyxoviridae virus. 
     Said animal of said first biological family is preferably selected from the group consisting of an animal of the family canidae, an animal of the family felidae and an animal of the family suidae, and wherein said animal of said first biological family is most preferably a canine, feline or swine such as a dog, cat or pig 
     Optionally, said Paramyxoviridae virus capable of infecting an animal of a first biological family is a CDV and said disease-causing agent capable of infecting an animal of said first biological family is a Canine Parvovirus (CPV) or, optionally said Paramyxoviridae virus capable of infecting an animal of a first biological family is a La Piedad Michoacan Mexico virus (LPMV) and said disease-causing agent capable of infecting an animal of said first biological family is a swine influenza virus (SwIV). 
     As another preferred option, said Paramyxoviridae virus capable of infecting an animal of a first biological family is a La Piedad Michoacan Mexico virus (LPMV) and said disease-causing agent capable of infecting an animal of said first biological family is a porcine epidemic diarrhea virus (PEDV). 
     According to a particularly preferred aspect, said nucleotide sequence of interest encodes an antigen from a canine parvovirus (CPV), feline parvovirus (FPV) or swine influenza virus (SwIV). 
     As another preferred option, said nucleotide sequence of interest preferably encodes an antigen from a porcine epidemic diarrhea virus (PEDV). 
     Said nucleotide sequence of interest preferably encodes
         a Protoparvovirus capsid protein, and wherein said Protoparvovirus capsid protein is preferably selected from the group consisting of Carnivore protoparvovirus 1 (CPV or FPV) capsid protein, Primate protoparvovirus 1 capsid protein, Rodent protoparvovirus 1 capsid protein, Rodent protoparvovirus 2 capsid protein, Ungulate parvovirus 1 (PPV) capsid protein, or   an influenza virus envelope protein, wherein said envelope protein is optionally hemagglutinin and/or wherein said influenza virus is optionally selected from the group consisting of influenza A virus, influenza B virus and influenza C virus, and wherein the influenza A virus is preferably selected from the group of the influenza viruses H3N2, H3N1, H1N1, H1N2, H2N1, H2N3 and H911.       

     As another preferred option, said nucleotide sequence of interest encodes a coronavirus Spike (S) protein, and wherein said coronavirus S protein is preferably selected from the group consisting of Alpaca coronavirus S protein, Alphacoronavirus 1 S protein, Human coronavirus 229E S protein, Human Coronavirus NL63 S protein, Porcine epidemic diarrhea virus (PEDV) S protein, Human coronavirus OC43 S protein, Human coronavirus HKU1 S protein, Murine coronavirus S protein, Severe acute respiratory syndrome-related coronavirus (SASS-CoV) S protein, Middle East respiratory syndrome-related coronavirus (MERS-CoV) S protein and Avian infectious bronchitis virus (IBV) S protein. 
     In particular, said nucleotide sequence of interest encodes
         a Canine Parvovirus (CPV) VP2 protein, and wherein said CPV VP2 protein preferably comprises or consists of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35; or   an H3-subtype hemagglutinin (H3), in particular H3 of a swine influenza virus, and wherein said H3 preferably comprises or consists of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:36.       

     As another preferred option, said nucleotide sequence of interest encodes a porcine epidemic diarrhea virus (PEDV) spike (S) protein, and wherein said PEDV S protein preferably comprises or consists of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:45. 
     More preferably, said nucleotide sequence of interest encodes
         a Canine Parvovirus (CPV) VP2 protein, and wherein said sequence encoding a CPV VP2 protein in particular consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:15; or   an H3-subtype hemagglutinin (H3), preferably H3 of a swine influenza virus, and wherein said sequence encoding H3 preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:16.       

     As another preferred option, said nucleotide sequence of interest encodes a porcine epidemic diarrhea virus (PEDV) spike (S) protein, and wherein said sequence encoding a PEDV S protein preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:37 or SEQ ID NO:38. 
     According to another preferred aspect according to the invention, said expression cassette consists of or said Paramyxoviridae virus vector comprises
         a polynucleotide having an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:17 or SEQ ID NO:18, or   a polynucleotide having an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:19 or SEQ ID NO:20.       

     As another preferred option, said expression cassette consists of or said Paramyxoviridae virus vector comprises a polynucleotide having an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:39 or SEQ ID NO:40. 
     Preferably, the Paramyxoviridae virus vector of the present invention comprises
         an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:21; or   an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:22.       

     As another preferred option, the Paramyxoviridae virus vector of the present invention comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:41. 
     According to a another preferred aspect, the Paramyxoviridae virus vector of the present invention further comprises
         a sixth RNA sequence flanking the 5′ end of the fourth RNA sequence, wherein said sixth RNA sequence consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:23, and/or   a seventh RNA sequence flanking the 3′ end of the fifth RNA sequence, wherein said seventh RNA sequence consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:24.       

     The invention further provides a canine distemper virus vector, also termed “vector for dual CDV-CPV immunization” herein, wherein said vector comprises a heterologous RNA sequence of interest, wherein said heterologous RNA sequence of interest is preferably located between a P gene and an M gene of a CDV, and wherein said heterologous RNA sequence of interest encodes a Canine Parvovirus (CPV) VP2 protein, and wherein said sequence encoding a CPV VP2 protein optionally consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:15, 
     and wherein preferably said heterologous RNA sequence of interest is operably linked to a gene start (GS) sequence located in 3′ direction of said heterologous RNA sequence, wherein said GS sequence is most preferably included in an exogenous 3′ non-coding region of an H gene of a CDV, and/or to the genome promoter of a CDV. 
     As another preferred option, said heterologous RNA sequence of interest encodes a CPV VP2 protein comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35. 
     Particularly, said heterologous RNA sequence of interest in the vector for dual CDV-CPV immunization is operably linked to
         an exogenous 3′ non-coding region of an H gene of a CDV, in particular to the GS sequence included therein, wherein said exogenous 3′ non-coding region of an H gene of a CDV preferably flanks the 3′ end of said heterologous RNA sequence of interest encoding a CPV VP2 protein, and/or   the genome promoter of a CDV.       

     The invention further provides a nucleic acid molecule, which encodes the expression cassette of the present invention or the Paramyxoviridae virus vector of the present invention, wherein said nucleic acid molecule is preferably a DNA molecule, and wherein said nucleic acid molecule is preferably an isolated nucleic acid molecule. 
     Additionally, the present invention provides a DNA molecule, which is also termed “the DNA molecule of the present invention” hereinafter, wherein said molecule comprises 
     (i) a DNA sequence encoding a polypeptide of interest,
 
(ii) a DNA sequence flanking the 3′ end of the sequence of (i) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:25,
 
(iii) a DNA sequence flanking the 5′ end of the sequence of (i) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:26, and
 
(iv) a DNA sequence flanking the 5′ end of the sequence of (iii) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence selected of SEQ ID NO:27.
 
     The DNA molecule of the present invention preferably further comprises 
     (v) a DNA sequence flanking the 5′ end of the sequence of (ii) and being at least 66% identical with the sequence of SEQ ID NO:28, and/or
 
(vi) a DNA sequence flanking the 3′ end of the sequence of (iv) and being at least 66% identical with the sequence of SEQ ID NO:28.
 
     Preferably, the DNA molecule of the present invention is an isolated DNA molecule. 
     According to another preferred aspect, the DNA molecule of the present invention further comprises 
     (vii) a DNA sequence flanking the 3′ end of the sequence of (v) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:29, and/or
 
(viii) a DNA sequence flanking the 5′ end of the sequence of (vi) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:30.
 
     Preferably, the sequence of (i) is
         a DNA sequence encoding a Canine Parvovirus (CPV) VP2 protein, and wherein said sequence is preferably a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:31, or   a DNA sequence encoding an H3-subtype hemagglutinin (H3), preferably H3 of a swine influenza virus, and wherein said sequence is preferably a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:32.       

     As another preferred option, the sequence of (i) is a DNA sequence encoding a PEDV S protein, and wherein said sequence is preferably a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:42 or SEQ ID NO:43. 
     According to another preferred aspect, the DNA molecule of the present invention comprises
         a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:33, or   a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:34.       

     As another preferred option, the DNA molecule of the present invention comprises a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:44. 
     The invention further provides a mammalian host cell containing
         the expression cassette of the present invention,   the Paramyxoviridae virus vector of the present invention or the vector for dual CDV-CPV immunization described herein, or   the DNA molecule of the present invention,
 
and wherein said mammalian host cell is preferably an isolated mammalian host cell.
       

     The present invention also provides
         the expression cassette of the present invention,   the Paramyxoviridae virus vector of the present invention, or   the DNA molecule of the present invention
 
for use as a medicament, preferably as a vaccine.
       

     Additionally, in the context of the invention, a DNA construct is provided comprising the DNA molecule of the present invention, wherein said DNA construct is in particular a DNA vector such as a plasmid. DNA vectors or plasmids into which the DNA molecule of the present invention can be inserted will be recognized by those of ordinary skill in the art. The DNA construct, as described herein, is preferably an isolated DNA construct. As used herein, the term “comprising the DNA molecule” is in particular understood to be equivalent to the term “comprising the sequence of the DNA molecule”. 
     Further, the present invention provides an RNA transcript of the DNA construct described herein, wherein said RNA transcript is preferably an isolated RNA transcript. 
     The present invention also provides a cell transfected with the DNA construct described herein, wherein said cell is preferably an isolated cell. 
     Further, the present invention provides a cell transfected with the RNA transcript mentioned herein, wherein said cell is preferably an isolated cell. 
     Preferably, the cell or mammalian host cell, respectively, is a Vero cell. 
     Furthermore, in the context of the present invention, a method for the preparation of an infectious Paramyxoviridae virus containing a heterologous gene, in particular for preparing the Paramyxoviridae virus vector of the present invention is provided, wherein said method comprises the steps of: 
     a. providing a host cell expressing a heterologous RNA polymerase;
 
b. transfecting the host cell with the DNA construct described herein, and wherein the DNA molecule of the present invention included in the DNA construct is transcribed by the heterologous RNA polymerase, and
 
c. isolating the viruses produced by the cells.
 
     Since a Paramyxoviridae virus has a negative stranded RNA genome, the presence of an RNA polymerase, preferably of T7 RNA polymerase or the RNA polymerase encoded by the Paramyxoviridae virus, in the transfected cells is required. Most preferred is the use of the T7 RNA polymerase. The presence of the RNA polymerase in the transfected cells can be provided, for instance, by co-transfection of a plasmid coding for and expressing the RNA polymerase or by penetrating the cells with RNA polymerase protein. According to the invention, in this regard, the use of transgenic cells producing RNA polymerase is particularly preferred, such as the transfection of the DNA construct into BHK-21 cells expressing T7 polymerase or into BSR-T7/5 cells. Alternatively, the cells can also be transfected with the mRNA that codes for the RNA polymerase and which is translated into the RNA polymerase when transfected into the host cells. 
     According to another aspect, the invention further provides the use of the Paramyxoviridae virus vector of the invention or of the cell described herein for the manufacture of an immunogenic composition or a vaccine. 
     In still another aspect, the present invention also provides an immunogenic composition, which is also termed “the immunogenic composition of the present invention” herein, wherein said immunogenic composition comprises 
     a. the Paramyxoviridae virus vector of the present invention, wherein said vector is optionally an infectious and/or attenuated virus or wherein said vector is optionally an attenuated and/or modified live virus, and
 
b. a recombinant protein expressed by said vector and/or a virus like particle comprising a plurality of a recombinant protein expressed by said vector, and
 
c. optionally a pharmaceutical- or veterinary-acceptable carrier or excipient, preferably said carrier is suitable for oral, intradermal, intramuscular or intranasal application.
 
     Preferably, said recombinant protein expressed by the vector is
         a parvovirus VP2 antigen such as CPV VP2 protein, or   an influenza virus envelope protein, wherein said envelope protein is optionally hemagglutinin such as H3.       

     It is in particular understood that the phrase “expressed by said vector” or “expressed by the vector”, respectively, as used herein, is in particular equivalent to “expressed in a cell infected with the vector” or “expressed in a cell infected with said vector”, respectively. 
     According to another preferred aspect, the immunogenic composition of the present invention comprises or consists of 
     a. any of the above mentioned vectors encoding a CPV VP2 protein, and wherein said vector is preferably a CDV vector, in particular the CDV vector of the present invention, or a vector for dual CDV-CPV immunization, as described herein, and
 
b. a polypeptide comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35 or SEQ ID NO:36, wherein said polypeptide is preferably a recombinant protein expressed by said vector,
 
c. and optionally a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is preferably suitable for oral, intradermal, intramuscular or intranasal application.
 
     As another preferred option, said recombinant protein expressed by said vector is a coronavirus S protein, and wherein said coronavirus S protein is optionally a PEDV S protein, in particular comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:45. 
     The invention also provides a vaccine or pharmaceutical composition, which is hereinafter also termed “the vaccine or the pharmaceutical composition of the present invention, wherein said vaccine or pharmaceutical composition comprises 
     a. any of the vectors described herein in the context of the present invention, and
 
b. a recombinant protein expressed by said vector and/or a virus like particle comprising a plurality of a recombinant protein expressed by said vector, and
 
c. a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is preferably suitable for oral, intradermal, intramuscular or intranasal application, and
 
d. optionally said vaccine further comprises an adjuvant,
 
and wherein said recombinant protein expressed by the vector is preferably
         parvovirus VP2 antigen such as CPV VP2 protein, or   an influenza virus envelope protein, wherein said envelope protein is optionally hemagglutinin such as H3.       

     Preferably, the vaccine or pharmaceutical composition of the present invention comprises or consists of 
     a. any of the above mentioned vectors encoding a CPV VP2 protein or an influenza virus hemagglutinin, and wherein said vector is preferably a CDV vector, in particular the CDV vector of the present invention, or a vector for dual CDV-CPV immunization, as described herein, and
 
b. a polypeptide comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35 or SEQ ID NO:36, wherein said polypeptide is preferably a recombinant protein expressed by said vector, and
 
c. a pharmaceutical- or veterinary-acceptable carrier or excipient, preferably said carrier is suitable for oral, intradermal, intramuscular or intranasal application,
 
d. and optionally an adjuvant.
 
     As another preferred option, said recombinant protein expressed by said vector, which is included in the vaccine or pharmaceutical composition of the present invention, is a coronavirus S protein, and wherein said coronavirus S protein is optionally a PEDV S protein, in particular comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:45. 
     The present invention further provides a method for the preparation of an immunogenic composition or a vaccine for reducing the incidence or the severity of one or more clinical signs associated with or caused by an infection, comprising the following steps: 
     a. infecting a mammalian host cell with any of the vectors described herein in the context of the present invention,
 
b. cultivating the infected cells under suitable conditions,
 
c. collecting infected cell cultures,
 
d. optionally purifying the collected infected cell cultures of step c)
 
e. optionally mixing said collected infected cell culture with a pharmaceutically acceptable carrier,
 
and wherein the immunogenic composition or vaccine is preferably reducing the severity of one or more clinical signs associated with or caused by
         an infection with CDV and CPV, or   an infection with an influenza virus, wherein said influenza virus is optionally selected from the group consisting of influenza A virus, influenza B virus and influenza C virus, and wherein the influenza A virus is preferably selected from the group of the influenza viruses H3N2, H3N1, H1N1, H1N2, H2N1, H2N3 and H911.       

     As another preferred option, said immunogenic composition or vaccine reduces the severity of one or more clinical signs associated with or caused by an infection with a coronavirus, wherein said coronavirus is optionally selected from the group consisting of Alpaca coronavirus, Alphacoronavirus 1, Human coronavirus 229E, Human Coronavirus NL63, Porcine epidemic diarrhea virus (PEDV), Human coronavirus OC43, Human coronavirus HKU1, Murine coronavirus, Severe acute respiratory syndrome-related coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV) and Avian infectious bronchitis virus (IBV). 
     The present invention also relates to
         the immunogenic composition of the present invention or   the vaccine or pharmaceutical composition of the present invention
 
for use in a method of reducing or preventing the clinical signs or disease caused by an infection with at least one pathogen in an animal or for use in a method of treating or preventing an infection with at least one pathogen in an animal, preferably said animal is a companion animal, such as a canine or feline and/or any other domestic or wild carnivore, or a food producing animal such as swine, and wherein said infection with at least one pathogen is preferably
   an infection with CDV and/or CPV, wherein said infection is most preferably an infection with CDV and/or CPV, or   an infection with swine influenza virus, wherein the swine influenza virus is optionally a subtype H3 influenza virus, and wherein said subtype H3 influenza virus is preferably a swine influenza virus of the subtype H3N2 or H3N1.       

     As another preferred option, said infection with at least one pathogen is an infection with PEDV. 
     In particular, the present invention also relates to the immunogenic composition or the vaccine of the present invention or the pharmaceutical composition of the present invention for use in a method for
         inducing an immune response against CPV and CDV in an animal, preferably in a canine, or   inducing an immune response against swine influenza virus in a pig, wherein the swine influenza virus is optionally a subtype H3 influenza virus, and wherein said subtype H3 influenza virus is preferably a swine influenza virus of the subtype H3N2 or H3N1.       

     As another preferred option, the immunogenic composition or the vaccine of the present invention or the pharmaceutical composition of the present invention is for use in a method for inducing an immune response against PEDV in a pig, in particular in a preferably pregnant sow. 
     In one aspect, the immunogenic composition or the vaccine of the present invention or the pharmaceutical composition of the present invention is for use in a method of reducing or preventing the clinical signs or disease caused by an infection with a PEDV in a piglet, wherein the piglet is to be suckled by a sow to which the immungenic composition has been adminstered, and wherein said sow is preferably a sow to which the immunogenic composition has been administered while/when said sow has been pregnant, in particular with said piglet. 
     According to a particular preferred aspect of the present invention, in such use the immunogenic composition or the vaccine of the present invention or the pharmaceutical composition of the present invention is to be administered mucosally, preferably intranasally, such as to said sow. 
     Additionally, the present invention provides a method of immunizing an animal such as a companion animal, such as a canine or feline and/or any other domestic or wild carnivore, or a food producing animal including swine against a clinical disease caused by at least one pathogen in said animal, said method comprising the step of administering to the animal the immunogenic composition of the present invention or the vaccine or pharmaceutical composition of the present invention, wherein said immunogenic composition or vaccine fails to cause clinical signs of infection but is capable of inducing an immune response that immunizes the animal against pathogenic forms of said at least one pathogen, and wherein said at least one pathogen is preferably CDV or CPV or SwIV or, most preferably, CDV and CPV. 
     The present invention further provides a method for inducing the production of antibodies specific for PEDV in a sow, wherein said method comprises administering the immunogenic composition of the present invention or the vaccine or pharmaceutical composition of the present invention, in particular comprising a Paramyxoviridae virus vector of the present invention encoding a PEDV S protein comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:45, to said sow. 
     Further, the present invention in particular provides a method of reducing or preventing the clinical signs or disease caused by an infection with a PEDV in a piglet, wherein said method comprises
         administering the immunogenic composition of the present invention or the vaccine or pharmaceutical composition of the present invention, in particular comprising a Paramyxoviridae virus vector of the present invention encoding a PEDV S protein comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:45, to a sow, and   allowing said piglet to be suckled by said sow.       

     Preferably, said sow is a sow being pregnant, in particular with said piglet 
     More preferably, such method of reducing or preventing the clinical signs or disease caused by an infection with a PEDV in a piglet, comprises the steps of
         administering the immunogenic composition of the present invention or the vaccine or pharmaceutical composition of the present invention, in particular comprising a Paramyxoviridae virus vector of the present invention encoding a PEDV S protein comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:45, to a sow being pregnant with said piglet,   allowing said sow to give birth to said piglet, and   allowing said piglet to be suckled by said sow.       

     Preferably, the immunogenic composition of the present invention or the vaccine or pharmaceutical composition of the present invention is administered to the animal intramuscularly or mucosally, such as by intranasal administration. 
     Most preferably in such method of reducing or preventing the clinical signs or disease caused by an infection with a PEDV in a piglet said immunogenic composition or said vaccine or pharmaceutical composition is administered mucosally, preferably intranasally, to said sow. 
     According to still another preferred aspect, the present invention also provides a kit for inducing an immune response against at least one pathogen in an animal or for vaccinating an animal, preferably a companion animal, such as a canine or feline and/or any other domestic or wild carnivore, or food producing animal such as swine or cattle, against a disease associated with at least one pathogen and/or reducing the incidence or the severity of one or more clinical signs associated with or caused by at least one pathogen in an animal comprising:
     a) a syringe or a dispenser capable of administering a vaccine to said animal; and   b) the immunogenic composition of the present invention or the vaccine or pharmaceutical composition of the present invention, and   c) optionally an instruction leaflet,
 
wherein said at least one pathogen is preferably CDV or CPV or SwIV or PEDV, and wherein said at least one pathogen is most preferably CDV and CPV.
   

     Definitions 
     Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs at the time of filing. The meaning and scope of terms should be clear; however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Herein, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms such as “includes” and “included” is not limiting. All patents and publications referred to herein are incorporated by reference herein. 
     The practice of the present invention will employ, unless otherwise indicated, conventional techniques of virology, molecular biology, microbiology, recombinant DNA technology, protein chemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch &amp; Maniatis, Molecular Cloning: A Laboratory Manual, Vols. I, II and III, Second Edition (1989); DNA Cloning, Vols. I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames &amp; S. J. Higgins eds. 1984); Animal Cell Culture (R. K. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL press, 1986); Perbal, B., A Practical Guide to Molecular Cloning (1984); the series, Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Protein purification methods—a practical approach (E.L.V. Harris and S. Angal, eds., IRL Press at Oxford University Press); and Handbook of Experimental Immunology, Vols. I-IV (D. M. Weir and C. C. Blackwell eds., 1986, Blackwell Scientific Publications). 
     Before describing the present invention in detail, it is to be understood that this invention is not limited to particular DNA, polypeptide sequences or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting. It must be noted that, as used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “an antigen” includes a mixture of two or more antigens, reference to “an excipient” includes mixtures of two or more excipients, and the like. 
     Paramyxoviridae Definitions 
     It is in particular understood that the term “Paramyxoviridae virus”, as used herein, is equivalent to the term “paramyxovirus”, as frequently used in the context of viruses of the family Paramyxoviridae. 
     The term “5′ non-coding region of an N gene of a Paramyxoviridae virus”, as used herein, in particular relates to an RNA sequence of an expressable N gene of a preferably infectious Paramyxoviridae virus, said RNA sequence flanking the 5′ end of the coding sequence (i.e. the 5′ end of the RNA triplet complementary to the stop codon) and comprising the gene end sequence of said gene. Thus, more particular, the “5′ non-coding region sequence”, as mentioned herein, is an RNA sequence identical to the entire 5′ non-coding sequence of an expressable N gene of a preferably infectious Paramyxoviridae virus. Still more particular, the “5′ non-coding region”, as mentioned herein, is an RNA sequence identical to the non-coding sequence of an N gene of a Paramyxoviridae virus, wherein said non-coding sequence is flanked by (a) the coding sequence and (b) the intergenic sequence connecting said N gene with the P gene. 
     The term “3′ non-coding region” of a specific gene (e.g. H gene) of a Paramyxoviridae virus, as used herein, in particular relates to an RNA sequence of an expressable specific gene (e.g. H gene) of a preferably infectious Paramyxoviridae virus, said RNA sequence flanking the 3′ end of the coding sequence (i.e. the 3′ end of the RNA triplet complementary to the start codon) and comprising the gene start sequence of said gene. Thus, more particular, the “3′ non-coding region sequence”, as mentioned herein, is an RNA sequence identical to the entire 3′ non-coding sequence of an expressable specific gene (e.g. H gene) of a preferably infectious Paramyxoviridae virus. Still more particular, the “3′ non-coding region”, as mentioned herein, is an RNA sequence identical to the non-coding sequence of a specific gene (e.g. H, gene) of a Paramyxoviridae virus, wherein said non-coding sequence is flanked by (a) the coding sequence and (b) the intergenic sequence connecting said gene with the next gene in 3′ direction. 
     As used herein, the term “intergenic region” in particular refers to the RNA sequence connecting the 5′ end of a gene of a Paramyxoviridae virus with the 3′ start of the adjacent gene in 5′ direction of a Paramyxoviridae virus. 
     The term “gene start sequence”, as used herein, is in particular equivalent to the term “gene start signal”. 
     As used herein, it is understood that the term “genome promoter of a Paramyxoviridae virus” is equivalent to the term “genome leader sequence of a Paramyxoviridae virus”, and that the term “genome promoter of a CDV” is equivalent to the term “genome leader sequence of a CDV”, respectively. 
     Molecular Biology Definitions 
     The phrase “sequence flanking the 5′ end of” as described herein is in particular equivalent to the phrase “sequence covalently linked with the 5′ end of” or, respectively, with the phrase “sequence, wherein the 3′ terminal nucleotide thereof is covalently linked with the 5′ terminal nucleotide of”, and wherein it is particularly understood that said two terminal nucleotides are linked covalently between the phosphate group attached to the 5′ carbon of the pentose and the 3′ carbon atom of the adjacent pentose. 
     The phrase “sequence flanking the 3′ end of” as described herein is in particular equivalent to the phrase “sequence covalently linked with the 3′ end of” or, respectively, to the phrase “sequence, wherein the 5′ terminal nucleotide thereof is covalently linked with the 3′ terminal nucleotide of”, and wherein it is particularly understood that said two terminal nucleotides are linked covalently between the 3′ carbon atom of the pentose and the phosphate group attached to the 5′ carbon of the adjacent pentose. 
     It is understood, that the term “Kozak sequence” as used in the context of the present invention in particular relates to a nucleotide sequence which codes for an mRNA sequence taking part in the recognition of a translational start site by the ribosome. Preferably, an RNA sequence encoding a Kozak sequence in the context of the present invention is an RNA sequence which may be transcribed into a sequence of an mRNA molecule flanking the 5′ end of the start codon (AUG) therein and playing a role in the initiation of the translation process. 
     The term “vector” as it is known in the art refers to a polynucleotide construct, typically a plasmid or a bacterial artificial chromosome, used to transmit genetic material to a host cell. Vectors can be, for example, bacteria, viruses, phages, bacterial artificial chromosomes, cosmids, or plasmids. A vector as used herein can be composed of or contain either DNA or RNA. In some embodiments, a vector is composed of DNA. In some embodiments a vector is an infectious virus. Such a viral vector contains a viral genome which was manipulated in a way that it carries a foreign gene which has no function in the replication of the viral vector neither in cell culture nor in a host animal. According to specific aspects of the present disclosure a vector may be used for various aspects such as mere transmission of genetic material, for the transfection of host cells or organisms, for use as vaccines, e.g. DNA vaccines or for gene expression purposes. Gene expression is a term describing the biosynthesis of a protein in a cell as directed by a specific polynucleotide sequence called gene. In a specific aspect a vector may be an “expression vector”, which is a vector that is capable of directing the expression of a protein encoded by one or more genes carried by the vector when it is present in the appropriate environment. 
     Vectors and methods for making and/or using vectors (or recombinants) for expression can be by or analogous to the methods disclosed in: U.S. Pat. Nos. 4,603,112, 4,769,330, 5,174,993, 5,505,941, 5,338,683, 5,494,807, 4,722,848, 5,942,235, 5,364,773, 5,762,938, 5,770,212, 5,942,235, 382,425, PCT publications WO 94/16716, WO 96/39491, WO 95/30018; Paoletti, “Applications of pox virus vectors to vaccination: An update, “PNAS USA 93: 11349-11353, October 1996; Moss, “Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety,” PNAS USA 93: 11341-11348, October 1996; Smith et al., U.S. Pat. No. 4,745,051 (recombinant baculovirus); Richardson, C. D. (Editor), Methods in Molecular Biology 39, “Baculovirus Expression Protocols” (1995 Humana Press Inc.); Smith et al., “Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector”, Molecular and Cellular Biology, December, 1983, Vol. 3, No. 12, p. 2156-2165; Pennock et al., “Strong and Regulated Expression of  Escherichia coli  B-Galactosidase in Infect Cells with a Baculovirus vector, “Molecular and Cellular Biology March 1984, Vol. 4, No. 3, p. 406; EPAO 370 573; U.S. application No. 920,197, filed Oct. 16, 1986; EP Patent publication No. 265785; U.S. Pat. No. 4,769,331 (recombinant herpesvirus); Roizman, “The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors,” PNAS USA 93:11307-11312, October 1996; Andreansky et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,” PNAS USA 93: 11313-11318, October 1996; Robertson et al., “Epstein-Barr virus vectors for gene delivery to B lymphocytes”, PNAS USA 93: 11334-11340, October 1996; Frolov et al., “Alphavirus-based expression vectors: Strategies and applications,” PNAS USA 93: 11371-11377, October 1996; Kitson et al., J. Virol. 65, 3068-3075, 1991; U.S. Pat. Nos. 5,591,439, 5,552,143; WO 98/00166; allowed U.S. application Ser. Nos. 08/675,556, and 08/675,566 both filed Jul. 3, 1996 (recombinant adenovirus); Grunhaus et al., 1992, “Adenovirus as cloning vectors,” Seminars in Virology (Vol. 3) p. 237-52, 1993; Ballay et al. EMBO Journal, vol. 4, p. 3861-65, Graham, Tibtech 8, 85-87, April, 1990; Prevec et al., J. Gen Virol. 70, 42434; PCT WO 91/11525; Felgner et al. (1994), J. Biol. Chem. 269, 2550-2561, Science, 259: 1745-49, 1993; and McClements et al., “Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease”, PNAS USA 93: 11414-11420, October 1996; and U.S. Pat. Nos. 5,591,639, 5,589,466, and 5,580,859, as well as WO 90/11092, WO93/19183, WO94/21797, WO95/11307, WO95/20660; Tang et al., Nature, and Furth et al., Analytical Biochemistry, relating to DNA expression vectors, inter alia. See also WO 98/33510; Ju et al., Diabetologia, 41: 736-739, 1998 (lentiviral expression system); Sanford et al., U.S. Pat. No. 4,945,050; Fischbach et al. (Intracel); WO 90/01543; Robinson et al., Seminars in Immunology vol. 9, pp. 271-283 (1997), (DNA vector systems); Szoka et al., U.S. Pat. No. 4,394,448 (method of inserting DNA into living cells); McCormick et al., U.S. Pat. No. 5,677,178 (use of cytopathic viruses); and U.S. Pat. No. 5,928,913 (vectors for gene delivery); as well as other documents cited herein. 
     The term “viral vector” describes a genetically modified virus which was manipulated by recombinant DNA technique in a way so that its entry into a host cell results in a specific biological activity, e.g. the expression of a transgene carried by the vector. In a specific aspect the transgene is an antigen. A viral vector may or may not be replication competent in the target cell, tissue, or organism. It is in particular understood, that the term “viral vector”, as used herein, is equivalent to the term “virus vector”. 
     Generation of a viral vector can be accomplished using any suitable genetic engineering techniques well known in the art, including, without limitation, the standard techniques of restriction endonuclease digestion, ligation, transformation, plasmid purification, DNA sequencing, transfection in cell cultures, for example as described in Sambrook et al. (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, N.Y. (1989)) or K. Maramorosch and H. Koprowski (Methods in Virology Volume VIII, Academic Press Inc. London, UK (2014)). 
     A viral vector can incorporate sequences from the genome of any known organism. The sequences can be incorporated in their native form or can be modified in any way to obtain a desired activity. For example, the sequences can comprise insertions, deletions or substitutions. 
     A viral vector can include coding regions for two or more proteins of interest. For example, the viral vector can include the coding region for a first protein of interest and the coding region for a second protein of interest. The first protein of interest and the second protein of interest can be the same or different. In some embodiments, the viral vector can include the coding region(s) for a third or a fourth protein of interest. The third and the fourth protein of interest can be the same or different. The total length of the two or more proteins of interest encoded by one viral vector can vary. For example, the total length of the two or more proteins can be at least about 200 amino acids. At least about 250 amino acids, at least about 300 amino acids, at least about 350 amino acids, at least about 400 amino acids, at least about 450 amino acids, at least about 500 amino acids, at least about 550 amino acids, at least about 600 amino acids, at least about 650 amino acids, at least about 700 amino acids, at least about 750 amino acids, at least about 800 amino acids, or longer. 
     The terms “viral vector” and “viral construct” can be used interchangeably. 
     The term “construct”, as used herein, refers to a recombinant nucleic acid such as a plasmid, a BAC, or a recombinant virus that has been artificially generated. 
     The term “plasmid” refers to cytoplasmic DNA that replicates independently of the bacterial chromosome within a bacterial host cell. In a specific aspect of the present invention the term “plasmid” and/or “transfer plasmid” refers to an element of recombinant DNA technology useful for construction of e.g. an expression cassette for insertion into a viral vector. In another specific aspect the term “plasmid” may be used to specify a plasmid useful for DNA vaccination purposes. 
     As used herein, the terms “nucleic acid” and “polynucleotide” are interchangeable and refer to any nucleic acid. The term “nucleic acid sequence” is understood to be equivalent to the term “nucleotide sequence”. The term “nucleotide sequence” is understood to be equivalent to the term “polynucleotide sequence”. 
     The term “nucleic acid”, “nucleic acid sequence”, “nucleotide sequence”, “polynucleotide”, “polynucleotide sequence”, “RNA sequence” or “DNA sequence” as used herein refers to an oligonucleotide, nucleotide or polynucleotide and fragments and portions thereof and to DNA or RNA of genomic or synthetic origin, which may be single or double stranded and represent the sense or antisense strand. The sequence may be a non-coding sequence, a coding sequence or a mixture of both. The nucleic acid sequences of the present invention can be prepared using standard techniques well known to one of skill in the art. 
     The terms “nucleic acid” and “polynucleotide” also specifically include nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil). 
     As used herein, the term “promoter” or “promoter sequence” means a nucleotide sequence that permits binding of RNA polymerase and directs the transcription of a gene. Typically, a promoter is located in the 5′ non-coding region of a gene, proximal to the transcriptional start site of the gene. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. Examples of promoters include, but are not limited to, promoters from bacteria, yeast, plants, viruses, and animals such as mammals (including horses, pigs, cattle and humans), birds or insects. A promoter can be inducible, repressible, and/or constitutive. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as a change in temperature (Ptashne, 2014). Examples of promoters well known to the person skilled in the art are for example SV40 large T, HCMV and MCMV immediate early gene 1, human elongation factor alpha promoter, baculovirus polyhedrin promoter. 
     The term “complementary nucleotide sequences” describes one strand of the two paired strands of polynucleotides such as DNA or RNA. The nucleotide sequence of the complementary strand mirrors the nucleotide sequence of its paired strand so that for each adenosin it contains a thymin (or uracil for RNA), for each guanine a cytosin, and vice versa. The complementary nucleotide sequence of e.g. 5′-GCATAC-3′ is 3′-CGTATG-5′ or for RNA 3′-CGUAUG-5′. 
     The terms “gene”, “gene of interest”, as used herein have the same meaning and refer to a polynucleotide sequence of any length that encodes a product of interest. The gene may further comprise regulatory sequences preceding (5′ non-coding or untranslated sequences) and following (3′ non-coding or untranslated sequences) the coding sequence. The selected sequence can be full length or truncated, a fusion or tagged gene, and can be a cDNA, a genomic DNA, or a DNA fragment. It is generally understood that genomic DNA encoding for a polypeptide or RNA may include non-coding regions (i.e. introns) that are spliced from mature messenger RNA (mRNA) and are therefore not present in cDNA encoding for the same polypeptide or RNA. It can be the native sequence, i.e. naturally occurring form(s), or can be mutated, or comprising sequences derived from different sources or otherwise modified as desired. These modifications include codon optimizations to optimize codon usage in the selected host cell or tagging. Furthermore they can include removal or additions of cis-acting sites such as (cryptic) splice donor, acceptor sites and branch points, polyadenylation signals, TATA-boxes, chi-sites, ribosomal entry sites, repeat sequences, secondary structures (e.g. stem loops), binding sites for transcription factors or other regulatory factors, restriction enzyme sites etc. to give just a few, but not limiting examples. The selected sequence can encode a secreted, cytoplasmic, nuclear, membrane bound or cell surface polypeptide. 
     “Essential gene” or “essential genes”, respectively, as used herein is in particular intended to encompass genes that are obligatory for replication in the host cell. 
     The term “nucleotide sequence of interest” as used herein is a more general term than gene of interest as it does not necessarily comprise a gene but may comprise elements or parts of a gene or other genetic information, e.g. on/(origin of replication). A nucleotide sequence of interest may be any DNA or RNA sequence independently of whether it comprises a coding sequence or not. 
     The term “transcription” describes the biosynthesis of mRNA in a cell. 
     The term “expression” as used herein refers to transcription and/or translation of a nucleic acid sequence within a host cell. According to specific aspects of the present invention the term “expression” refers to transcription and/or translation of a heterologous and/or exogenous nucleic acid sequence within a host cell. The level of expression of a desired product in a host cell may be determined on the basis of either the amount of corresponding RNA or mRNA that is present in the cell, or the amount of the desired polypeptide encoded by the selected sequence. For example, mRNA transcribed from a selected sequence can be quantitated by Northern blot hybridization, ribonuclease RNA protection, in situ hybridization to cellular RNA or by RTqPCR (reverse transcription followed by quantitative PCR). Proteins expressed from a selected sequence can be quantitated by various methods, e.g. by ELISA, by Western blotting, by radioimmunoassays, by immunoprecipitation, by assaying for the biological activity of the protein, or by immunostaining of the protein followed by FACS analysis. 
     The term “expression cassette” or “transcription unit” or “expression unit” defines a region within a vector, construct or polynucleotide sequence that contains one or more genes to be transcribed, wherein the nucleotide sequences encoding the transcribed gene(s) as well as the polynucleotide sequences containing the regulatory elements contained within an expression cassette are operably linked to each other. They are transcribed from a promoter and transcription is terminated by at least one polyadenylation signal. In one specific aspect, they are transcribed from one single promoter. As a result, the different genes are at least transcriptionally linked. More than one protein or product can be transcribed and expressed from each transcription unit (multicistronic transcription unit). Each transcription unit will comprise the regulatory elements necessary for the transcription and translation of any of the selected sequences that are contained within the unit. And each transcription unit may contain the same or different regulatory elements. For example, each transcription unit may contain the same terminator, IRES element or introns may be used for the functional linking of the genes within a transcription unit. A vector or polynucleotide sequence may contain more than one transcription 
     The term “viral titre” is a measure of infectious units per volume of a virus preparation. Viral titre is an endpoint in a biological procedure and is defined as the dilution at which a certain proportion of tests carried out in parallel show an effect (Reed and Muench, 1938). Specifically the tissue culture infectious dose fifty per milliliter (TCID50/ml) gives the dilution of a virus preparation at which 50% of a number of cell cultures inoculated in parallel with that dilution are infected. 
     “Transcription-regulatory elements” normally comprise a promoter upstream of the gene sequence to be expressed, transcription initiation and termination sites and a polyadenylation signal. 
     The term “transcription initiation site” refers to a nucleic acid in the construct corresponding to the first nucleic acid incorporated into the primary transcript, i.e. the mRNA precursor. The transcription initiation site may overlap with the promoter sequences. 
     The “termination signal” or “terminator” or “polyadenylation signal” or “polyA” or transcription termination site” or “transcription termination element” is a signal sequence which causes cleavage at a specific site at the 3′ end of the eukaryotic mRNA and post-transcriptional incorporation of a sequence of about 100-200 adenine nucleotides (polyA tail) at the cleaved 3′ end, and thus causes RNA polymerase to terminate transcription. The polyadenylation signal comprises the sequence AATAAA about 10-30 nucleotides upstream of the cleavage site and a sequence located downstream. Various polyadenylation elements are known such as tk polyA, SV40 late and early polyA, BGH polyA (described for example in U.S. Pat. No. 5,122,458) or hamster growth hormone polyA (WO2010010107). 
     “Translation regulatory elements” comprise a translation initiation site (AUG), a stop codon and a polyA signal for each individual polypeptide to be expressed. An internal ribosome entry site (IRES) may be included in some constructs. In order to optimize expression it may be advisable to remove, add or alter 5′- and/or 3′-untranslated regions of the nucleic acid sequence to be expressed to eliminate any potentially extra inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the level of transcription or translation. Consensus ribosome binding sites (Kozak sequence) can be inserted immediately upstream of the start codon to enhance translation and thus expression. Increased A/U contents around this ribosome binding site further a more efficient ribosome binding. 
     By definition, every polynucleotide sequence or every gene inserted in a host cell and the respective protein or RNA encoded thereby is referred to as “exogenous”, “exogenous sequence”, “exogenous gene”, “exogenous coding sequence”, with respect to the host cell, when it comes from a different (virus) species. As used herein in respect to a sequence or gene of interest such as an antigen the term “exogenous” means that said sequence or gene of interest, specifically said antigen is expressed out of its natural species context. Accordingly, the CPV VP2 antigen is one example (see example 2) of an exogenous antigen in respect to the Paramyxoviridae virus vector. As used herein, the term “exogenous RNA” or “exogenous nucleic acid sequence” in particular refers to a nucleic acid sequence that was introduced into the genome of a Paramyxoviridae virus from an external source, such as from a recombinant sequence. Examples of such external source comprise Paramyxoviridae virus sequences as well as non Paramyxoviridae virus derived sequences. More particular, the introduction of the exogenous nucleic acid sequence results in a genome or a gene, respectively, having a non-naturally occurring portion. As used herein, the term “exogenous RNA” thus in particular refers to a nucleotide sequence, which is not naturally found in the Paramyxoviridae virus genome. Such non-naturally occurring portion or not naturally found sequence, respectively, can also be the result of the insertion of one naturally occurring nucleotide sequence into another naturally occurring nucleotide sequence. 
     By definition, every polynucleotide sequence or every gene inserted in a host cell and the respective protein or RNA encoded thereby is referred to as “heterologous, “heterologous sequence”, “heterologous gene”, “heterologous coding sequence”, “transgene” or “heterologous protein” with respect to the host cell. This applies even if the sequence to be introduced or the gene to be introduced is identical to an endogenous sequence or an endogenous gene of the host cell. For example, a 5′ non-coding region of an N gene of a Paramyxoviridae virus introduced into a Paramyxoviridae viral vector at a different site or in modified form than in the Paramyxoviridae wild type virus is by definition a heterologous sequence. As used herein in respect to a sequence or gene of interest such as an antigen, the term “heterologous” means that said sequence or gene of interest, specifically said antigen, is expressed out of its natural subspecies context. 
     The term “non-naturally occurring” means any sequence or gene of interest such as an antigen, which is not occurring in this context naturally, such as a hybrid sequence or a sequence or gene of interest such as an antigen from a different species, or sequence or gene of interest such as an antigen, which is not a product of nature due to artificial mutation, insertion, deletion or the like. 
     The term “recombinant” is used exchangeably with the terms “non-naturally occurring”, “heterologous” and “exogenous” throughout the specification of this present invention. Thus, a “recombinant” protein is a protein expressed from a either a heterologous or an exogenous polynucleotide sequence. The term recombinant as used with respect to a virus, means a virus produced by artificial manipulation of the viral genome. A virus comprising a heterologous or an exogenous sequence such as an exogenous antigen encoding sequence is a recombinant virus. The term recombinant virus and the term non-naturally occurring virus are used interchangeably. 
     Thus, the term “heterologous vector” means a vector that comprises a heterologous or an exogenous polynucleotide sequence. The term “recombinant vector” means a vector that comprises a heterologous or a recombinant polynucleotide sequence. 
     As used herein, the term “operably linked” is used to describe the connection between regulatory elements and a gene or its coding region. Typically, gene expression is placed under the control of one or more regulatory elements, for example, without limitation, constitutive or inducible promoters, tissue-specific regulatory elements, and enhancers. A gene or coding region is said to be “operably linked to” or “operatively linked to” or “operably associated with” the regulatory elements, meaning that the gene or coding region is controlled or influenced by the regulatory element. For instance, a promoter is operably linked to a coding sequence if the promoter effects transcription or expression of the coding sequence. 
     It is in particular understood in the context of the present invention that the term “being [ . . . ] identical with the sequence” is equivalent to the term “having [ . . . ] sequence identity with the sequence”. 
     As used herein, it is in particular understood that the term “being at least X % identical with the sequence of SEQ ID NO:Y” is equivalent to the term “being at least X % identical with the sequence of SEQ ID NO:Y over the length of SEQ ID NO:Y” or to the term “being at least X % identical with the sequence of SEQ ID NO:Y over the entire length of SEQ ID NO:Y”, respectively. In this context, “X” is any number from 66 to 100, in particular any integer selected from 66 to 100, such that “X % sequence identity” represents any of the percent sequence identities mentioned herein. Respectively, “Y” in this context is any integer selected from 1 to 45, such that “SEQ ID NO:Y” represents any of the SEQ ID NOs mentioned herein. 
     It is furthermore understood that the term “being at least 99% identical”, as described herein, also (in one extreme of the range) comprises and relates to the term “being 100% identical” or “being identical with the sequence”, respectively. 
     “Sequence Identity” as it is known in the art refers to a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, namely a reference sequence and a given sequence to be compared with the reference sequence. Sequence identity is determined by comparing the given sequence to the reference sequence after the sequences have been optimally aligned to produce the highest degree of sequence similarity, as determined by the match between strings of such sequences. Upon such alignment, sequence identity is ascertained on a position-by-position basis, e.g., the sequences are “identical” at a particular position if at that position, the nucleotides or amino acid residues are identical. The total number of such position identities is then divided by the total number of nucleotides or residues in the reference sequence to give % sequence identity. Sequence identity can be readily calculated by known methods, including but not limited to, those described in Computational Molecular Biology, Lesk, A. N., ed., Oxford University Press, New York (1988), Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology, von Heinge, G., Academic Press (1987); Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York (1991); and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988), the teachings of which are incorporated herein by reference. Preferred methods to determine the sequence identity are designed to give the largest match between the sequences tested. Methods to determine sequence identity are codified in publicly available computer programs which determine sequence identity between given sequences. Examples of such programs include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research, 12(1):387 (1984)), BLASTP, BLASTN and FASTA (Altschul, S. F. et al., J. Molec. Biol., 215:403-410 (1990). The BLASTX program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al., NCVI NLM NIH Bethesda, Md. 20894, Altschul, S. F. et al., J. Molec. Biol., 215:403-410 (1990), the teachings of which are incorporated herein by reference). These programs optimally align sequences using default gap weights in order to produce the highest level of sequence identity between the given and reference sequences. As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 85%, preferably 90%, 91%, 92%, 93%, 94%, even more preferably 95%, 96%, 97%, 98%, 99%, 99.9% “sequence identity” to a reference nucleotide sequence, it is intended that the nucleotide sequence of the given polynucleotide is identical to the reference sequence except that the given polynucleotide sequence may include up to 15, preferably up to 10, even more preferably up to 5 point mutations per each 100 nucleotides of the reference nucleotide sequence. In other words, in a polynucleotide having a nucleotide sequence having at least 85%, preferably 90%, 91%, 92%, 93%, 94%, even more preferably 95%, 96%, 97%, 98%, 99%, 99.9% identity relative to the reference nucleotide sequence, up to 15%, preferably 10%, 9%, 8%, 7%, 6%, even more preferably 5%, 4%, 3%, 2%, 1%, 0.1% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 15%, preferably 10%, 9%, 8%, 7%, 6%, even more preferably 5%, 4%, 3%, 2%, 1%, 0.1% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5′ or 3′ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Analogously, by a polypeptide having a given amino acid sequence having at least, for example, 85%, preferably 90%, 91%, 92%, 93%, 94%, even more preferably 95%, 96%, 97%, 98%, 99% sequence identity to a reference amino acid sequence, it is intended that the given amino acid sequence of the polypeptide is identical to the reference sequence except that the given polypeptide sequence may include up to 15, preferably up to 10, 9, 8, 7, 6, even more preferably up to 5, 4, 3, 2, 1 amino acid alterations per each 100 amino acids of the reference amino acid sequence. In other words, to obtain a given polypeptide sequence having at least 85%, preferably 90%, 91%, 92%, 93%, 94%, even more preferably 95%, 96%, 97%, 98%, 99% sequence identity with a reference amino acid sequence, up to 15%, preferably up to 10%, 9%, 8%, 7%, even more preferably up to 5%, 4%, 3%, 2%, 1% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 15%, preferably up to 10%, 9%, 8%, 7%, even more preferably up to 5%, 4%, 3%, 2%, 1% of the total number of amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or the carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in the one or more contiguous groups within the reference sequence. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. However, conservative substitutions are not included as a match when determining sequence identity. 
     The terms “sequence identity” or “percent identity” are used interchangeably herein. For the purpose of this invention, it is defined here that in order to determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid for optimal alignment with a second amino or nucleic acid sequence). The amino acid or nucleotide residues at corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid or nucleotide residue as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=number of identical positions/total number of positions (i.e. overlapping positions)×100). Preferably, the two sequences are the same length. 
     A sequence comparison may be carried out over the entire lengths of the two sequences being compared or over fragment of the two sequences. Typically, the comparison will be carried out over the full length of the two sequences being compared. However, sequence identity may be carried out over a region of, for example, twenty, fifty, one hundred or more contiguous amino acid residues. 
     The skilled person will be aware of the fact that several different computer programs are available to determine the identity between two sequences. For instance, a comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid or nucleic acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48): 444-453 (1970)) algorithm which has been incorporated into the GAP program in the Accelrys GCG software package (available at http://www.accelrys.com/products/gcg/), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. The skilled person will appreciate that all these different parameters will yield slightly different results but that the overall percentage identity of two sequences is not significantly altered when using different algorithms. 
     The protein sequences or nucleic acid sequences of the present invention can further be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the BLASTN and BLASTP programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST protein searches can be performed with the BLASTP program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25(17): 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., BLASTP and BLASTN) can be used. See the homepage of the National Center for Biotechnology Information at http://www.ncbi.nlm.nih.gov/. 
     Vaccine Definitions 
     An “immunogenic or immunological composition” refers to a composition of matter that comprises at least one antigen, or immunogenic portion thereof, that elicits an immunological response in the host of a cellular or antibody-mediated immune response to the composition. 
     The term “antigen” used herein is well understood in the art and includes substances which are immunogenic, i.e., immunogens, as well as substances which induce immunological unresponsiveness, or anergy, i.e., a lack of reactions by the body&#39;s defense mechanisms to foreign substances. As used herein, the term “antigen” is intended to mean full length proteins as well as peptide fragments thereof containing or comprising epitope. 
     The term “food producing animal” means animals which are used for human consumption such as swine, cattle, poultry, fish and the like, preferably food producing animal means swine and cattle, most preferably swine. 
     An “immunogenic composition” as used herein can refer to a polypeptide or a protein, such as for example a viral surface protein that elicits an immunological response as described herein. The term “immunogenic fragment” or “immunogenic portion” refers to a fragment or truncated and/or substituted form of a protein or polypeptide that includes one or more epitopes and thus elicits the immunological response described herein. In general, such truncated and/or substituted forms, or fragments will comprise at least six contiguous amino acids from a full-length protein. Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, N.J. For example, linear epitopes may be determined by concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known and described in the art, see e.g., U.S. Pat. No. 4,708,871; Geysen et al. (1984) Proc. Natl. Acad. Sci. USA 81:3998-4002; and Geysen et al. (1986) Molec. Immunol. 23:709-715. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and two-dimensional nuclear magnetic resonance. See Epitope Mapping Protocols, supra. Synthetic antigens are also included within the definition, for example, polyepitopes, flanking epitopes, and other recombinant or synthetically derived antigens. See, e.g., Bergmann et al. (1993) Eur. J. Immunol. 23:2777-2781; Bergmann et al. (1996), J. Immunol. 157:3242-3249; Suhrbier, A. (1997), Immunol. and Cell Biol. 75:402-408; and Gardner et al., (1998) 12th World AIDS Conference, Geneva, Switzerland, June 28-Jul. 3, 1998. (The teachings and content of which are all incorporated by reference herein.) 
     The term “vaccine” as used herein refers to a pharmaceutical composition comprising at least one immunologically active component that induces an immunological response in an animal and possibly but not necessarily one or more additional components that enhance the immunological activity of the active component. A vaccine may additionally comprise further components typical to pharmaceutical compositions. By way of distinction the immunologically active component of a vaccine may comprise complete virus particles in either their original form or as attenuated particles in a so called modified live vaccine (MLV) or particles inactivated by appropriate methods in a so called killed vaccine (KV). In another form the immunologically active component of a vaccine may comprise appropriate elements of the organisms (subunit vaccines) whereby these elements are generated either by destroying the whole particle or the growth cultures containing such particles and optionally subsequent purification steps yielding the desired structure(s), or by synthetic processes including an appropriate manipulation by use of a suitable system based on, for example, bacteria, insects, mammalian, or other species plus optionally subsequent isolation and purification procedures, or by induction of the synthetic processes in the animal needing a vaccine by direct incorporation of genetic material using suitable pharmaceutical compositions (polynucleotide vaccination). A vaccine may comprise one or simultaneously more than one of the elements described above. As used within specific aspects of the present invention “vaccine” refers to a live vaccine or live virus, also called recombinant vaccine. In another specific aspect of the present invention “vaccine” refers to an inactivated or killed virus including virus like particles (VLPs). Thus, a vaccine may be a subunit vaccine or a killed (KV) or inactivated vaccine. 
     The term “Multiplicity of Infection (M.O.I.)” describes how many infectious units, e.g. TCID50, of a virus preparation are used per cell to infect cultured cells. For example, a M.O.I. of 0.01 means that for every 100 cells in a culture vessel one infectious unit is inoculated. 
     The term “DNA vaccination” or “polynucleotide vaccination” means direct inoculation of genetic material using suitable pharmaceutical compositions. 
     Various physical and chemical methods of inactivation are known in the art. The term “inactivated” refers to a previously virulent or non-virulent virus or bacterium that has been irradiated (ultraviolet (UV), X-ray, electron beam or gamma radiation), heated, or chemically treated to inactivate or kill such virus or bacterium while retaining its immunogenicity. Suitable inactivating agents include beta-propiolactone, binary or beta- or acetyl-ethyleneimine, gluteraldehyde, ozone, and formalin (formaldehyde). 
     For inactivation by formalin or formaldehyde, formaldehyde is typically mixed with water and methyl alcohol to create formalin. The addition of methyl alcohol prevents degradation or cross reaction during the in activation process. One embodiment uses about 0.1 to 1% of a 37% solution of formaldehyde to inactivate the virus or bacterium. It is critical to adjust the amount of formalin to ensure that the material is inactivated but not so much that side effects from a high dosage occur. 
     More particularly, the term “inactivated” in the context of a virus means that the virus is incapable of replication in vivo or in vitro and, respectively, the term “inactivated” in the context of a bacterium means that the bacterium is incapable of reproduction in vivo or in vitro. For example, the term “inactivated” may refer to a virus that has been propagated in vitro, and has then been inactivated using chemical or physical means so that it is no longer capable of replicating. In another example, the term “inactivated” may refer to a bacterium that has been propagated, and then inactivated using chemical or physical means resulting in a suspension of the bacterium, fragments or components of the bacterium, such as resulting in a bacterin which may be used as a component of a vaccine. 
     As used herein, the terms “inactivated”, “killed” or “KV” are used interchangeably. 
     The term “live vaccine” refers to a vaccine comprising either a living organism or a replication competent virus or viral vector. 
     A “pharmaceutical composition” essentially consists of one or more ingredients capable of modifying physiological, e.g., immunological functions, of the organism it is administered to, or of organisms living in or on the organism. The term includes, but is not restricted to, antibiotics or antiparasitics, as well as other constituents commonly used to achieve certain other objectives such as, but not limited to, processing traits, sterility, stability, feasibility to administer the composition via enteral or parenteral routes such as oral, intranasal, intravenous, intramuscular, subcutaneous, intradermal, or other suitable route, tolerance after administration, or controlled release properties. One non-limiting example of such a pharmaceutical composition, solely given for demonstration purposes, could be prepared as follows: cell culture supernatant of an infected cell culture is mixed with a stabilizer (e.g., spermidine and/or bovine serum albumin (BSA) and the mixture is subsequently lyophilized or dehydrated by other methods. Prior to vaccination, the mixture is then rehydrated in aqueous (e.g., saline, phosphate buffered saline (PBS) or non-aqueous solutions (e.g., oil emulsion, aluminum-based adjuvant). 
     As used herein, “pharmaceutical- or veterinary-acceptable carrier” includes any and all solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like. In some preferred embodiments, and especially those that include lyophilized immunogenic compositions, stabilizing agents for use in the present invention include stabilizers for lyophilization or freeze-drying. 
     In some embodiments, the immunogenic composition of the present invention contains an adjuvant. “Adjuvants” as used herein, can include aluminum hydroxide and aluminum phosphate, saponins e.g., Quil A, QS-21 (Cambridge Biotech Inc., Cambridge Mass.), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, Ala.), water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion. The emulsion can be based in particular on light liquid paraffin oil (European Pharmacopea type); isoprenoid oil such as squalane or squalene; oil resulting from the oligomerization of alkenes, in particular of isobutene or decene; esters of acids or of alcohols containing a linear alkyl group, more particularly plant oils, ethyl oleate, propylene glycol di-(caprylate/caprate), glyceryl tri-(caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, in particular isostearic acid esters. The oil is used in combination with emulsifiers to form the emulsion. The emulsifiers are preferably nonionic surfactants, in particular esters of sorbitan, of mannide (e.g. anhydromannitol oleate), of glycol, of polyglycerol, of propylene glycol and of oleic, isostearic, ricinoleic or hydroxystearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Pluronic products, especially L121. See Hunter et al., The Theory and Practical Application of Adjuvants (Ed.Stewart-Tull, D. E. S.), JohnWiley and Sons, NY, pp51-94 (1995) and Todd et al., Vaccine 15:564-570 (1997). Exemplary adjuvants are the SPT emulsion described on page 147 of “Vaccine Design, The Subunit and Adjuvant Approach” edited by M. Powell and M. Newman, Plenum Press, 1995, and the emulsion MF59 described on page 183 of this same book. 
     A further instance of an adjuvant is a compound chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative. Advantageous adjuvant compounds are the polymers of acrylic or methacrylic acid which are cross-linked, especially with polyalkenyl ethers of sugars or polyalcohols. These compounds are known by the term carbomer (Phameuropa Vol. 8, No. 2, June 1996). Persons skilled in the art can also refer to U.S. Pat. No. 2,909,462 which describes such acrylic polymers cross-linked with a polyhydroxylated compound having at least 3 hydroxyl groups, preferably not more than 8, the hydrogen atoms of at least three hydroxyls being replaced by unsaturated aliphatic radicals having at least 2 carbon atoms. The preferred radicals are those containing from 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups. The unsaturated radicals may themselves contain other substituents, such as methyl. The products sold under the name CARBOPOL®; (BF Goodrich, Ohio, USA) are particularly appropriate. They are cross-linked with an allyl sucrose or with allyl pentaerythritol. Among then, there may be mentioned Carbopol 974P, 934P and 971P. Most preferred is the use of CARBOPOL® 971P. Among the copolymers of maleic anhydride and alkenyl derivative, are the copolymers EMA (Monsanto), which are copolymers of maleic anhydride and ethylene. The dissolution of these polymers in water leads to an acid solution that will be neutralized, preferably to physiological pH, in order to give the adjuvant solution into which the immunogenic, immunological or vaccine composition itself will be incorporated. 
     Further suitable adjuvants include, but are not limited to, the RIM adjuvant system (Ribi Inc.), Block co-polymer (CytRx, Atlanta Ga.), SAF-M (Chiron, Emeryville Calif.), monophosphoryl lipid A, Avridine lipid-amine adjuvant, heat-labile enterotoxin from  E. coli  (recombinant or otherwise), cholera toxin, IMS 1314 or muramyl dipeptide, or naturally occurring or recombinant cytokines or analogs thereof or stimulants of endogenous cytokine release, among many others. 
     It is expected that an adjuvant can be added in an amount of about 100 μg to about 10 mg per dose, preferably in an amount of about 100 μg to about 10 mg per dose, more preferably in an amount of about 500 μg to about 5 mg per dose, even more preferably in an amount of about 750 μg to about 2.5 mg per dose, and most preferably in an amount of about 1 mg per dose. Alternatively, the adjuvant may be at a concentration of about 0.01 to 50%, preferably at a concentration of about 2% to 30%, more preferably at a concentration of about 5% to 25%, still more preferably at a concentration of about 7% to 22%, and most preferably at a concentration of 10% to 20% by volume of the final product. 
     “Diluents” can include water, saline, dextrose, ethanol, glycerol, and the like. Isotonic agents can include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others. Stabilizers include albumin and alkali salts of ethylendiamintetracetic acid, among others. 
     “Isolated” means altered “by the hand of man” from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or polypeptide naturally present in a living organism is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein. 
     “Attenuation” means reducing the virulence of a pathogen. In the present invention “attenuation” is synonymous with “avirulent”. In the present invention, an attenuated virus is one in which the virulence has been reduced so that it does not cause clinical signs of infection but is capable of inducing an immune response in the target animal, but may also mean that the clinical signs are reduced in incidence or severity in animals infected with the attenuated virus, especially the Paramyxoviridae virus vector as claimed, in comparison with a “control group” of animals infected with non-attenuated virus or pathogen and not receiving the attenuated virus. In this context, the term “reduce/reduced” means a reduction of at least 10%, preferably 25%, even more preferably 50%, still more preferably 60%, even more preferably 70%, still more preferably 80%, even more preferably 90% and most preferably of 100% as compared to the control group as defined above. Thus, an attenuated, avirulent pathogen such as for example an attenuated viral vector as claimed, especially the Paramyxoviridae virus vector (preferably CDV vector) as claimed, is suitable for the generation of a modified live vaccine (MLV) or modified live immunogenic composition. 
     Herein, “effective dose” means, but is not limited to, an amount of antigen that elicits, or is able to elicit, an immune response that yields a reduction of clinical symptoms in an animal to which the antigen is administered. 
     As used herein, the term “effective amount” means, in the context of a composition, an amount of an immunogenic composition capable of inducing an immune response that reduces the incidence of or lessens the severity of infection or incident of disease in an animal. Particularly, an effective amount refers to colony forming units (CFU) per dose. Alternatively, in the context of a therapy, the term “effective amount” refers to the amount of a therapy which is sufficient to reduce or ameliorate the severity or duration of a disease or disorder, or one or more symptoms thereof, prevent the advancement of a disease or disorder, cause the regression of a disease or disorder, prevent the recurrence, development, onset, or progression of one or more symptoms associated with a disease or disorder, or enhance or improve the prophylaxis or treatment of another therapy or therapeutic agent. 
     An “immune response” or “immunological response” means, but is not limited to, the development of a cellular and/or antibody-mediated immune response to the (immunogenic) composition or vaccine of interest. Usually, an immune or immunological response includes, but is not limited to, one or more of the following effects: the production or activation of antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest. Preferably, the host will display either a therapeutic or a protective immunological (memory) response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction in number of symptoms, severity of symptoms, or the lack of one or more of the symptoms associated with the infection of the pathogen, a delay in the of onset of viremia, reduced viral persistence, a reduction in the overall viral load and/or a reduction of viral excretion. 
     “Protection against disease”, “protective immunity”, “functional immunity”, “reduction of clinical symptoms”, “induction/production of neutralizing antibodies and/or serum conversion”, and similar phrases, means a partial or complete response against a disease or condition generated by administration of one or more therapeutic compositions of the invention, or a combination thereof, that results in fewer deleterious effects than would be expected in a non-immunized subject that has been exposed to disease or infection. That is, the severity of the deleterious effects of the infection are lessened in a vaccinated subject. Infection may be reduced, slowed, or possibly fully prevented, in a vaccinated subject. Herein, where complete prevention of infection is meant, it is specifically stated. If complete prevention is not stated then the term includes partial prevention. 
     The term “neutralizing antibody” relates to an antibody that is capable of keeping an infectious agent, usually a virus, e.g., CDV or CPV, from infecting a cell by neutralizing or inhibiting its biological effect. Neutralization can happen when antibodies bind to specific viral antigens, blocking the pathogen from entering their host cells. In one example it prevents the virus from binding to its receptor(s) and getting its genetic material inside the cell. 
     The term “antibody” or “immunoglobulin,” as used interchangeably herein, includes whole antibodies and any antigen binding fragment (antigen-binding portion) or single chain cognates thereof. An “antibody” comprises at least one heavy (H) chain and one light (L) chain. In naturally occurring IgGs, for example, these heavy and light chains are inter-connected by disulfide bonds and there are two paired heavy and light chains, these two also inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as V H ) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as V L ) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The V H  and V L  regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR) or Joining (J) regions (JH or JL in heavy and light chains respectively). Each V H  and V L  is composed of three CDRs three FRs and a J domain, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, J. The variable regions of the heavy and light chains bind with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) or humoral factors such as the first component (Clq) of the classical complement system. 
     Herein, “reduction of the incidence and/or severity of clinical signs” or “reduction of clinical symptoms” means, but is not limited to, reducing the number of infected subjects in a group, reducing or eliminating the number of subjects exhibiting clinical signs of infection, or reducing the severity of any clinical signs that are present in one or more subjects, in comparison to wild-type infection. For example, it should refer to any reduction of pathogen load, pathogen shedding, reduction in pathogen transmission, or reduction of any clinical sign symptomatic of malaria. Preferably these clinical signs are reduced in one or more subjects receiving the therapeutic composition of the present invention by at least 10% in comparison to subjects not receiving the composition and that become infected. More preferably clinical signs are reduced in subjects receiving a composition of the present invention by at least 20%, preferably by at least 30%, more preferably by at least 40%, and even more preferably by at least 50%. 
     The term “increased protection” herein means, but is not limited to, a statistically significant reduction of one or more clinical symptoms which are associated with infection by an infectious agent in a vaccinated group of subjects vs. a non-vaccinated control group of subjects. The term “statistically significant reduction of clinical symptoms” means, but is not limited to, the frequency in the incidence of at least one clinical symptom in the vaccinated group of subjects is at least 10%, preferably 20%, more preferably 30%, even more preferably 50%, and even more preferably 70% lower than in the non-vaccinated control group after the challenge the infectious agent. 
     “Long-lasting protection” shall refer to “improved efficacy” that persists for at least 3 weeks, but more preferably at least 3 months, still more preferably at least 6 months. In the case of livestock, it is most preferred that the long lasting protection shall persist until the average age at which animals are marketed for meat. 
     The term “reduction of viremia” induced by a virus means, but is not limited to, the reduction of virus entering the bloodstream of an animal, wherein the viremia level, i.e. the number of virus DNA or RNA copies per mL of blood serum or the number of plaque forming colonies per deciliter of blood serum, is reduced in the blood serum of animals receiving the composition of the present invention by at least 50% in comparison to animals not receiving the composition and may become infected. More preferably, the viremia level is reduced in animals receiving the composition of the present invention by at least 90%, preferably by at least 99.9%, more preferably by at least 99.99%, and even more preferably by at least 99.999%. 
     As used herein, the term “viremia” is particularly understood as a condition in which virus particles reproduce and/or circulate in the bloodstream of an animal, in particular of a mammal, a bird, or of an insect. 
     “Safety” refers to the absence of adverse consequences in a vaccinated animal following vaccination, including but not limited to: potential reversion of a virus-based vaccine to virulence, clinically significant side effects such as persistent, systemic illness or unacceptable inflammation at the site of vaccine administration. 
     The terms “vaccination” or “vaccinating” or variants thereof, as used herein means, but is not limited to, a process which includes the administration of an immunogenic composition of the invention that, when administered to an animal, elicits, or is able to elicit—directly or indirectly—, an immune response in said animal. 
     “Mortality”, in the context of the present invention, refers to death caused by an infection, and includes the situation where the infection is so severe that an animal is euthanized to prevent suffering and provide a humane ending to its life. 
     Formulations 
     The subject to which the composition is administered is preferably an animal, including but not limited to cattle, horses, sheep, pigs, poultry (e.g. chickens), goats, cats, dogs, hamsters, mice and rats, most preferably the mammal is a swine. 
     The formulations of the invention comprise an effective immunizing amount of one or more immunogenic compositions and a physiologically acceptable vehicle. Vaccines comprise an effective immunizing amount of one or more immunogenic compositions and a physiologically acceptable vehicle. The formulation should suit the mode of administration. 
     The immunogenic composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The immunogenic composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. 
     Methods of Treatment 
     Preferred routes of administration include but are not limited to intranasal, oral, intradermal, and intramuscular. Administration in drinking water, most preferably in a single dose, is desirable. The skilled artisan will recognize that compositions of the invention may also be administered in one, two or more doses, as well as, by other routes of administration. For example, such other routes include subcutaneously, intracutaneously, intraperitnoeally, intracutaneously, and depending on the desired duration and effectiveness of the treatment, the compositions according to the invention may be administered once or several times, also intermittently, for instance on a daily basis for several days, weeks or months and in different dosages such as about 10 3  to 10 8 TCID50 (see viral titre above). In a specific aspect of the present invention the dosage is about 10 3  to 10 8  TCID50, especially for live virus/live vaccine. 
     The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration preferably for administration to a mammal, especially a pig. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. 
     Sequences Overview 
     The following sequences are detailed and disclosed hereby in the present invention, wherein the sequences in the sequence listing are presented in the 5′-end to 3′-end direction from left to right, and wherein: 
     SEQ ID NO:1 (RNA) corresponds to a 5′ non-coding region of an N gene of a CDV,
 
SEQ ID NO:2 (RNA) corresponds to a 5′ non-coding region of a P gene of a CDV,
 
SEQ ID NO:3 (RNA) corresponds to a 5′ non-coding region of a M gene of a CDV,
 
SEQ ID NO:4 (RNA) corresponds to a 5′ non-coding region of a F gene of a CDV,
 
SEQ ID NO:5 (RNA) corresponds to a 5′ non-coding region of an H gene of a CDV,
 
SEQ ID NO:6 (RNA) corresponds to a 5′ non-coding region of a L gene of a CDV,
 
SEQ ID NO:7 (RNA) corresponds to a 3′ non-coding region of an H gene of a CDV,
 
SEQ ID NO:8 (RNA) corresponds to a 3′ non-coding region of an N gene of a CDV,
 
SEQ ID NO:9 (RNA) corresponds to a 3′ non-coding region of an P gene of a CDV,
 
SEQ ID NO:10 (RNA) corresponds to a 3′ non-coding region of an M gene of a CDV,
 
SEQ ID NO:11 (RNA) corresponds to a 3′ non-coding region of an F gene of a CDV,
 
SEQ ID NO:12 (RNA) corresponds to a 3′ non-coding region of an L gene of a CDV,
 
SEQ ID NO:13 (RNA) corresponds to a sequence encoding a Kozak sequence,
 
SEQ ID NO:14 (RNA) corresponds to an intergenic sequence of a CDV,
 
SEQ ID NO:15 (RNA) corresponds to a sequence encoding a VP2 protein of a CPV,
 
SEQ ID NO:16 (RNA) corresponds to a sequence encoding a H3-subtype hemagglutinin,
 
SEQ ID NO:17 (RNA) corresponds to a combination of SEQ ID Nos: 14, 1, 15, 13 and 7,
 
SEQ ID NO:18 (RNA) corresponds to a combination of SEQ ID Nos: 1, 15, 13, 7 and 14,
 
SEQ ID NO:19 (RNA) corresponds to a combination of SEQ ID Nos: 14, 1, 16, 13 and 7,
 
SEQ ID NO:20 (RNA) corresponds to a combination of SEQ ID Nos: 1, 16, 13, 7 and 14,
 
SEQ ID NO:21 (RNA) corresponds to a combination of SEQ ID Nos: 14, 1, 15, 13, 7 and 14,
 
SEQ ID NO:22 (RNA) corresponds to a combination of SEQ ID Nos: 14, 1, 16, 13, 7 and 14,
 
SEQ ID NO:23 (RNA) corresponds to a sequence comprising the M, F, H and L gene of a CDV,
 
SEQ ID NO:24 (RNA) corresponds to a sequence comprising the N and P gene of a CDV,
 
SEQ ID NO:25 corresponds to a DNA reverse complement of SEQ ID NO:1,
 
SEQ ID NO:26 corresponds to a DNA reverse complement of SEQ ID NO:13,
 
SEQ ID NO:27 corresponds to a DNA reverse complement of SEQ ID NO:7,
 
SEQ ID NO:28 corresponds to a DNA reverse complement of SEQ ID NO:14,
 
SEQ ID NO:29 corresponds to a DNA reverse complement of SEQ ID NO:23,
 
SEQ ID NO:30 corresponds to a DNA reverse complement of SEQ ID NO:24,
 
SEQ ID NO:31 corresponds to a DNA reverse complement of SEQ ID NO:15,
 
SEQ ID NO:32 corresponds to a DNA reverse complement of SEQ ID NO:16,
 
SEQ ID NO:33 corresponds to a DNA reverse complement of SEQ ID NO:21,
 
SEQ ID NO:34 corresponds to a DNA reverse complement of SEQ ID NO:22,
 
SEQ ID NO:35 corresponds to an amino acid sequence of a CPV VP2,
 
SEQ ID NO:36 corresponds to an amino acid sequence of a H3-subtype hemagglutinin,
 
SEQ ID NO:37 (RNA) corresponds to a sequence encoding a PEDV S protein,
 
SEQ ID NO:38 (RNA) corresponds to a sequence encoding a PEDV S protein,
 
SEQ ID NO:39 (RNA) corresponds to a combination of SEQ ID Nos: 14, 1, 38, 13 and 7,
 
SEQ ID NO:40 (RNA) corresponds to a combination of SEQ ID Nos: 1, 38, 13, 7 and 14,
 
SEQ ID NO:41 (RNA) corresponds to a combination of SEQ ID Nos: 14, 1, 38, 13, 7 and 14,
 
SEQ ID NO:42 corresponds to a DNA reverse complement of SEQ ID NO:37,
 
SEQ ID NO:43 corresponds to a DNA reverse complement of SEQ ID NO:38,
 
SEQ ID NO:44 corresponds to a DNA reverse complement of SEQ ID NO:41,
 
SEQ ID NO:45 corresponds to an amino acid sequence of a PEDV S protein.
 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. 
         FIG. 1 . Schematic illustration of the organisation of canine distemper virus (CDV) vector genome carrying a canine parvovirus VP2 transgene. 
         FIG. 2 . Map of a DNA construct (plasmid) for the generation (rescue) of a CDV recombinant vector with an arrangement of exogenous RNA sequences, wherein the respective plasmid DNA sequences are named “H gene start UTR”, “Kozak seq”, “CPV-VP2” and “N gene UTR”. 
         FIG. 3 . Schematic representation of an exemplary arrangement of RNA sequences, in 5′ end to 3′ end direction from left to right: (A.) underlying principal scheme, (B.) arrangement in a Paramyxoviridae virus vector, (C.) arrangement in a CDV vector encoding a canine parvovirus (CPV) VP2, and wherein (D.) and (E.) illustrate the respective arrangement of the sequences as indicated by the SEQ ID NOs of the sequence listing. 
         FIG. 4 . Virus titres (TCID50) measured in supernatant fraction. The titres represent virus growth in the supernatant sampled by each 24 hour, starting from 1 day post infection during 6 days post infection; “SD”=“study day”. 
         FIG. 5 . CDV neutralizing titres during the course of the study of animals vaccinated with CDV-VP2 recombinant. Y axis indicates the maximum dilutions of sera which neutralized the virus in the assay (CDV strain derived from the Lederle strain). The neutralization titre (VNT [Virus Neutralization Test] titre) was measured before 1 st  vaccination on study day 0 (SD0), before 2 nd  vaccination on study day 21 (SD21) and three weeks after second vaccination on study day 42 (SD42). Individual animals are designated in the legends. 
         FIG. 6 . Canine parvovirus neutralization antibody titres during the course of the study from animals vaccinated with CDV-VP2 recombinant. Y axis indicates the maximum dilutions of sera which neutralized the virus in the assay (CPV). The neutralization titre (VNT [Virus Neutralization Test] titre) was measured before 1 st  vaccination on study day 0 (SD0), before 2 nd  vaccination on study day 21 (SD21) and three weeks after second vaccination on study day 42 (SD42). Individual animals are designated in the legends. 
         FIG. 7 . Antibody levels as determined by an H3-subtype hemagglutinin (H3) specific ELISA test of samples from animals vaccinated with CDV-H3 recombinant. Y axis indicates the readouts represented in OD values of sample dilutions 1:500 for two timepoints, i.e. samples taken from the animals before 1st vaccination on study day 0 (SD0) and after second vaccination on study day 45 (SD45). 
         FIG. 8 . Results of IFNγ-ELISpot assay after vaccination of H3N2-MDA-positive piglets with CDV-H3 recombinant. Y axis indicates the number of IFN gamma producing cells per million of PBMC (Y axis) in vaccinated animals (left bar, represents mean value for six animals) and non-vaccinated animals (right bar, represents mean value for three animals). 
     
    
    
     EXAMPLES 
     The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention. 
     Example 1 
     A) CPV-VP2 Expression by CDV Vectors 
     In an in vitro study using a CDV backbone derived from Lederle vaccine strain with an insert of the sequence of SEQ ID NO:17 between the P gene and the M gene (the vector thus comprising the sequence of SEQ ID NO:21), it was possible to show intracellular expression of canine parvovirus (type 2b) VP2 protein in CDV associated fluorescent focuses. Respective results were also achieved for a corresponding CDV vector (i.e. only differing in the sequence encoding the CPV VP2) encoding a canine parvovirus type 2c (CPV-2c) VP2 protein. Results obtained for both vectors by immunofluorescence indicate strong expression of VP2 protein of CPV in all CDV infected syncytia. VP2, in contrast to CDV antigens, accumulated in nuclei and partially in the cytoplasm of infected cells, which varies during the course of syncytia development and might indicate that CPV-VP2 has transient nucleus trafficking, although no putative nuclear localization sequence has been detected by a routine search within the VP2 gene, nor published in the scientific literature. 
     B) Genetic Stability 
     Both CDV vectors of Example 1 A) were evaluated by serial passages involving freeze-thaw cycles at the end of each passage in a Vero cell line (i.e. the CDV production cell line). For assessing the genetic stability of the recombinants, 20 serial cell passages on Vero cells were performed. Sequencing of recombinant clones revealed full genetic stability of the inserted -CPV VP2 sequence and flanking regions. The sequence (incl. mutations) coding for both proteins (at amino acid level) remained unchanged. Additionally, using immunofluoresecence (IF) and western blotting (WB), it was possible to demonstrate that strong VP2 expression was present in the cells infected with CDV-VP2 recombinants during the all passage levels. 
     C) In Vitro Growth 
     Both CDV vectors described in Example 1 A) and B) were grown in Vero cells. The peak titres of both recombinants in the roller bottle system were achieved at 144 hours post infection and the titres dramatically increased after freezeing/thawing cycle indicating the cellular association of the virus (similar to parental CDV virus). When compared with parental classical CDV-MLVs, the generated CDV recombinant vaccine candidates have very similar end-titres, acceptable for bio-processing. 
     In conclusion, both CDV vectors showed good growth kinetics on production in Vero cells, reaching peak titres at 6 days post infection in roller bottles. Both vectors showed strong expression characteristics of transgenes (VP2) as determined by IF and WB, qualifying them as a dual CDV-CPV vaccine candidate. In addition, both viruses were tested for genetic stability for 20 cell passages on Vero cells. Both viruses remained fully genetically stable, indicating that are susceptible for vaccine bio-processing. 
     Example 2 
     In Vivo Efficacy Study in Swine: 
     For the purpose of this experiment a group of 6 piglets were vaccinated with 1×10 5  TCID 50  of the recombinant CDV vector encoding CPV-2b VP2 (CDV-VP2-2b) of Example 1 at study day (SD) 0 and boosted with 2×10 4  TCID 50  at SD21. Both applications were performed intramuscularly (IM) in the neck (2 mL volume each dose). 
     Four animals served as negative control and were inoculated with Vero cell homogenates (2 mL) in the neck. Three animals served as sentinels and did not receive any treatment. 
     Inclusion Criteria:
         Pigs clinically healthy and normally developed for age       

     Exclusion Criteria:
         Pigs with injuries, congenital abnormalities or clinical signs of disease which interfered with the study as assessed by the Study Director or designee   Pigs with a weak body condition (weight &lt;5 kg)       

     All study animals were housed in facilities appropriate for their age and were kept under same controlled conditions. The room had either plain flooring or alternatively partly-perforated flooring suitable for the age of the animals with four pens of approximately 20 m 2  each. Before vaccination, the sentinel animals were removed from the group, kept in a separate pen, and were regrouped 12 h after vaccination. 
     Rooms were under negative pressure (−75 Pa) for biosafety reasons. Room temperature was according to the requirements of the age of the animals. Ventilation rate was approximately 9/h. Animals had 12 h light at &gt;80 lux and 12 h of no light. Environmental enrichment for the animals was provided. Water and feed was available ad libitum in appropriate quality and was managed in accordance with the pigs&#39; requirements at their age and standard procedures. 
     Laboratory results showed that the CDV vectors replicated in limited fashion in swine host, targeting lymphatic cells. The virus was detected mostly in lymph nodes, spleen or tonsils. 
     Furthermore, serum virus neutralization tests were performed to measure neutralizing antibodies to CDV and CPV, respectively, in the tests animals. 
     In the following, the protocol of the serum neutralization test for CDV is given: 
     Cell Preparation 1 Day Before Neutralization Test 
     
         
         
           
             Trypsinize highly confluent Vero cells and resuspend them in an appropriate volume of MEM Earle&#39;s media containing 5% FCS 
             Count cells in suspension and adjust to 7×10 5  cells/10 mL per 96-well plate 
             One plates is sufficient for 4 samples. 
             Seed 1004, of cell suspension/well into all wells of 96-well plates 
             Incubate plates at 37° C. in CO 2  incubator for 16-24 h 
           
         
       
    
     Limited Dilution of Serum Samples 
     
         
         
           
             Pre-dilute samples 1:4 with sterile PBS 
             Inactivate prediluted sera at 56° C. for 30 minutes 
             Add 604, of MEM Earle&#39;s media supplemented with 1% 100×Pen/Strep to each well of an empty 96-well plate from column 1-11 
             Add an additional 364, of MEM Earle&#39;s media supplemented with 1% 100×Pen/Strep to column 1 (A1-H1) 
             Add 244, of heat-inactivated serum sample to column 1 (corresponds to 1:5 dilution) (For each serum sample add 244, to 3 wells of column 1 to test serum in triplicates) 
             Perform twofold serial dilutions of sera by transferring 604, from column to column 
             Repeat until column 11 (corresponding to 1:5120 dilution) 
             Discard 604, from the last column 
           
         
       
    
     Dilution of CDV-Virus 
     
         
         
           
             Dilute CDV-virus to 200 TCID 50/100  μL in MEM Earle&#39;s media supplemented with 1% 100×Pen/Strep, calculate 6 mL per 96-well plate.
 
Incubation of Serum Samples with CDV-Virus
 
             Add 604, of diluted virus to all wells of column 1-11 of the 96-well plates containing sera dilutions. Start adding virus in column 11. 
             Gently agitate plates and incubate for 2 hours at 37° C., 5% CO 2    
           
         
       
    
     Incubation of Serum Sample+/−CDV-Virus on V.D.S Cells 
     
         
         
           
             Remove 60 μL media from 1 day old v.d.s cells cells in 96-well plates 
             After completion of the 2 hours incubation time transfer 1004, of each well from the serum-virus mixture to the corresponding wells of the v.d.s cell plates column 1-11 
             Add 1004, of MEM Earle&#39;s media containing 1% 100×Pen/Strep to all wells of column 12 (=cell only control) 
             Incubate plates for 3 days at 37° C., 5% CO 2    
             Read results by light microscopy observing the virus-induced cytopathic effect. 
           
         
       
    
     The results for the serum neutralization test for CDV are presented in  FIG. 5 . All animals had no CDV neutralizing antibodies at the beginning of the study (SD0). Three weeks after the first immunization (SD21, at the time of the second immunization) one animal had neutralizing antibodies against CDV. 21 days after the second immunization (SD42) all but one animal vaccinated with CDV-VP2 had produced significant levels of neutralization antibodies against canine distemper virus. In conjunction with the results of the serum neutralization test for CPV (where all animals strongly reacted to vaccination, including the animal which at SD42 had no CDV neutralization antibodies) and another orthogonal series of tests (c.f. Example 3) it was concluded that this one animal was successfully vaccinated, but that the immune response regarding CDV had shifted to a cellular response. 
     The serum neutralization test regarding CPV was performed respectively, the results of which are presented in  FIG. 6 . Concerning the efficacy, all animals vaccinated with CDV-VP2 seroconverted against canine parvovirus 2. Particular increase in neutralizing Ab titres was detected after 2 nd  vaccination (see  FIG. 6 ). The levels of neutralizing antibodies at 21 days after second immunization (SD42) reached the levels of 1:40 to 1:400, which according to the literature, represents a protective titre range in a real host (canids) (Glover et al. 2012, Taguchi et al. 2011). 
     Importantly, all sentinel animals remained CDV and CPV sero-negative until the end of the study, indicating that the recombinant CDV viruses were not spread from vaccinated animals to non-vaccinated animals upon vaccination. 
     Example 3 
     Immunogenicity in H3N2-MDA-Positive Piglets: 
     In this study, an Hemagglutinin (HA)-specific IgG ELISA and an IFNγ-ELISpot assay were employed for investigating the humoral and cellular immune response of swine influenza maternally derived antibody (MDA)-positive animals vaccinated with a CDV vector encoding H3 of SwIV. 
     The vaccination of the animals was performed in accordance with Example 2 with the differences that: the insert included in the CDV backbone had the sequence of SEQ ID NO:19 (thus the vector comprising the sequence of SEQ ID NO:22 encoding H3 of SwIV), the vector (named CDV-H3 in the following) was administered to five piglets being H3N2-MDA-positive (MDA+animals)) and one piglet considered to be (almost) H3N2 seronegative (or having low MDA, respectively), and three piglets served as negative control. 
     A) HA-Specific IgG ELISA 
     In the following, the protocol of the ELISA as used is provided: 
     Flat-bottom 96-well plates (Nunc MaxiSorp #44-2404-21) are coated with 1 μg/mL recombinant influenza hemagglutinin protein (Trenzyme) in carbonate buffer, pH 9.6 overnight at 4° C. On the next day the coating antigen is discarded and plates are washed 5 times with wash buffer (50 mM Tris/0.14M NaCl/0.05% Tween20, pH 8.0) and subsequently incubated. 1 h at room temperature with 200 μL per well of blocking buffer (50 mM Tris/0.14M NaCl/1% BSA, pH 8.0). Sample dilutions are prepared in Sample/Conjugate Diluent (50 mM Tris/0.14M NaCl/0.05% Tween20/1% BSA). Then 100 μl/well of samples and controls (in duplicate) are dispensed into designated wells, covered plates are incubated at RT for 1 hour. Plates are washed 5 times with wash buffer. Afterwards 100 μl of the 1:100.00 diluted HRP-conjugated goat α-Pig IgG-H+L detection antibody (Southern Biotech, Cat #6050-05) is added into each well, and the covered plates are incubated for 1 hour at RT in the dark. After the washing step (5 times with wash buffer), 100 μl/well of the TMB substrate solution (POD, ready to use; Sigma # T4444) is added and the plates are incubated for 5-15 min at RT in the dark. The reaction is stopped by adding 50 μl/well of stop solution (2N sulfuric acid) and the absorbance measured at 450 nm at the ELISA reader (Synergy 2, Biotek). 
     Using this ELISA, it was seen by means of samples taken from the animals on study day 45 (SD45) that the animals were medium responsive towards the vaccination (animals 1 and 5, see  FIG. 7 ) if the baseline levels of MDA were medium (&lt;OD 1.0 and &gt;OD 0.2), with the exception of animal 2 which predominantly responded by cell-mediated immune response (please see below). Animal 4 having low MDA OD 0.2) did show a high antibody response. In contrast, the two animals with high MDA levels above OD 1.0 (animals 3 and 6) did not show an increase of specific H3 antibodies upon vaccination. 
     B) IFNγ-ELISpot 
     Additionally, cellular immune response from CDV-H3 vaccinated animals was measured using ELISPOT. 
     In the following, the protocol of the ELISpot assay as used is provided: 
     ELISpot plates (96 wells) are coated with purified anti-IFN-γ antibody for at least 12 h. PBMC are thawed, washed twice in PBS (no calcium, no magnesium), counted using trypan blue, and adjusted in RPMI medium to be dispensed to 3×105 cells/well. After extensive washing of the plate containing the coating antibody with PBS, plate is blocked at least for 1 hour at 37° C. and 5% CO 2 . Cell culture medium is added containing 3 μg/ml of the polyclonal activator ConA (positive control of IFNγ release) or with different concentrations of the antigen, followed by seeding of the PBMCs. Wells containing only medium or unstimulated cells serve as negative controls. After stimulation for 48 h, plates are washed first two times with water then with PBS/0.01% Tween20. Plates are incubated at room temperature for 1.5 h using a detection biotinylated anti-IFNγ antibody, diluted in PBS/0.01% Tween20/0.1% BSA. Subsequently, streptavidin-alkaline phosphatase enzyme diluted in PBS/0.01% Tween20/0.1% BSA is added to the plates (in the dark, for 45 min incubation). Finally, NBT and 5-Bromo-4-Chloro-3-Indolyl Phosphate are used as substrate of the alkaline phosphatase (development phase takes place also in the dark). These substrate systems produce an insoluble NBT diformazan end product that is blue to purple in color and can be measured in a plate reader. After extensive washing with running tap water, plates are left overnight to ensure complete drying. Spot counting is performed using the C.T.L. ELISpot reader. 
     In the assay, recombinant H3 protein was used to stimulate isolated PBMC from the animals vaccinated with CDV-H3 recombinant. As shown in  FIG. 8 , in the samples of animals vaccinated with two shots (samples taken on study day 28 (SD28)), significantly more IFN gamma producing cells were detected than in PBMCs of non-vaccinated animals. Such induction of cellular immunity is known to improve the vaccine efficacy and faster clearance of the pathogen upon infection. Furthermore, the significant T-cell response of the animals, vaccinated with CDV recombinant expressing hemagglutinin (H3) of the influenza virus of swine, was generated despite the presence of strong (swine influenza) maternal immunity in the vaccinated animals. The presence of pre-existing maternal immunity in young animals often causes interference with active immunisation and is the main cause of vaccine failure in juvenile animals. These findings importantly implicate the characteristics of CDV biology in the vaccinated organism, leading to development of active immunity despite the presence of passively present maternal immunity. 
     Example 4 
     Vaccine Efficacy Study 
     Porcine epidemic diarrhea (PED) is a highly contagious swine disease that can have tremendous economic impact. While all age classes of pigs are susceptible to infection, severe clinical signs and mortality are mainly seen in suckling piglets. The causative agent is PED virus (PEDV), an enveloped, single positive-stranded RNA-virus of the genus Alphacoronavirus within the Coronaviridae virus family. In Europe, PEDV first occurred in the late 1970ies in England. Afterwards it spread through whole Europe causing sporadic outbreaks. In the late 1990ies, PEDV had disappeared from the European pig farms as evidenced by very low seroprevalence and non-existent disease reporting. Outbreaks and endemic infections were still reported from Asia where the disease has high impact on the productivity of industrialized pig farms. Starting from 2005, PED cases were again reported from Europe, i.e. Italy. After the introduction of an apparently highly virulent PEDV into the United States in 2013, cases were also reported from Central Europe, including Germany and neighboring countries. The latter cases were caused by related but distinct PEDV strains (so-called S-INDEL strains). In Germany, cases were reported starting from May 2014 with high morbidity and variable lethality in suckling pigs. 
     This study, in which a CDV backbone derived from Lederle vaccine strain with an insert of the sequence of SEQ ID NO:38 (encoding a PEDV Spike protein) between the P gene and the M gene (the vector thus comprising the sequence of SEQ ID NO:41) was tested as vector vaccine (named hereinafter “CDV PEDV-Spike vaccine” or “CDV PEDV-Spike vector vaccine”, respectively), included six sows and their offspring. 
     All animals were checked for PEDV by RT-qPCR targeting the S-gene, and PEDV-specific antibodies. Only negative animals were enrolled in the study. 
     Three treatment groups (see below) received randomly assigned animals:
         Group 1 (negative control): Two sows (designated #1 and #2), unvaccinated   Group 2 (positive control): Two sows (designated #3 and #4), unvaccinated   Group 3 (CDV_PEDV-Spike): Two sows (designated #5 and #6), vaccinated with CDV_PEDV-Spike vector vaccine.       

     The vaccination of the two sows of group 3 was done according to the following scheme, wherein the stock titer of the CDV_PEDV-Spike vaccine, defined by endpoint titration, was 7.94×10 4  TCID50/ml: 
     9 weeks prior to expected farrowing date: each of the two sows received 4 ml of the vaccine intranasally (2 ml in each nostril);
 
6 weeks prior to expected farrowing date: each of the two sows received 4 ml of the vaccine intranasally (2 ml in each nostril);
 
3 weeks prior to expected farrowing date: each of the two sows received 4 ml of the respective vaccine intranasally (2 ml in each nostril) and additionally 2 ml intramuscularly.
 
     Piglets born to sows of group 1 (13 piglets of sow #1 and 12 piglets of sow #2) were orally mock-inoculated. Piglets born to sows of group 2 (12 piglets of sow #3 and 14 piglets of sow #4), and group 3 (5 piglets of sow #5 and 15 piglets of sow #6) were orally challenged with a PEDV field strain (named “PEDV EU” hereinafter) at an age of 4 days of life. 
     For inoculation of piglets of groups 2 and 3, cell culture adapted PEDV EU was used. The titer was 2.15×10 5  TCID50/ml. Piglets of groups 2 and 3 were orally inoculated. In this case, each piglet received 1 ml of a 1:10 diluted viral stock (titer 2.15×10 4  TCID50) using 2 ml syringes. 
     Piglets of group 1 were orally mock-inoculated using 1 ml cell culture medium in 2 ml syringes. 
     During the whole trial, rectal swabs (COPAN plain swabs without medium) were taken at the day of inoculation and on day 1 to 10 post inoculation (pi) as well as day 14, 17 and 20/21 pi of all animals for RT-qPCR analyses. Additional rectal swabs were taken from 4 piglets of each sow prior to inoculation and two days post challenge for bacteriological examination. Moreover, clinical signs indicative for PED were recorded daily using the established standardized cumulative score system (see below). Blood samples were taken at the day of inoculation and day 14 and 20/21 pi (end of trial) or the day of euthanasia or death of the respective animal. 
     Clinical Monitoring 
     The established cumulative clinical score was used for daily monitoring for clinical signs indicative for PED (see table below). 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Cumulative clinical score for clinical signs indicative for PED 
               
            
           
           
               
               
               
               
            
               
                   
                 General 
                 Feed intake/ 
                 Gastrointestinal 
               
               
                 Score 
                 behaviour 
                 suckling 
                 symptoms 
               
               
                   
               
               
                 0 
                 Agile, attentive, 
                 Greedy suckling, 
                 Physiological 
               
               
                   
                 no abnormalities 
                 good filled stomach, 
                 feces 
               
               
                   
                   
                 intake of piglet feed 
               
               
                 1 
                 Slight depression 
                 Slow suckling, 
                 Pasty feces, 
               
               
                   
                   
                 hardly interested 
                 vomiting 
               
               
                   
                   
                 in piglet feed 
               
               
                 2 
                 Depression, 
                 Reluctant feed intake, 
                 Watery feces, 
               
               
                   
                 isolaton 
                 hardly interested in 
                 reddened anal 
               
               
                   
                 from group, 
                 suckling/piglet feed, 
                 region, vomiting 
               
               
                   
                 vocalisation 
                 sunken flanks 
               
               
                   
                 (moaning) 
               
               
                 3 
                 Lateral position, 
                 Total anorexia, 
                 Watery feces with 
               
               
                   
                 signs of severe 
                 decreasing of milk 
                 blood or fibrin added, 
               
               
                   
                 dehydration, low 
                 production of sow 
                 highly reddened anal 
               
               
                   
                 body temperature 
                   
                 region, vomiting 
               
               
                   
               
            
           
         
       
     
     Sample Preparation and Nucleic Acid Extraction 
     Rectal swabs were submerged in 1 ml Dulbecco&#39;s Modified Eagle Medium and incubated for 1 hour at room temperature. Viral RNA was extracted using either the QIAmp ViralRNA Mini Kit (Qiagen) or the NucleoMagVet-Kit in combination with the KingFisher extraction platform. The RNA was stored at −20° degree until further use. 
     Blood samples were centrifuged at 2031×g for 20 min at room temperature to obtain serum. The resulting serum was aliquoted and stored at −20° C. 
     Virus Detection 
     To detect PEDV shedding, RT-qPCR-systems targeting the S-gene of PEDV were used as previously described (Stadler et al., BMC Vet Res. 11:142 (2015)). Samples taken at days 0 to 7 dpi and at 10 and 20/21 dpi were tested for PEDV-genome. The amount of genome copies/μl was calculated using an in-house standard. 
     Antibody Detection 
     A commercial indirect ELISA (INgezim PEDV, INGENASA, Madrid, Spain) was performed with all sera according to the producer&#39;s manual. 
     Bacteriology 
     Fecal swabs of four piglets per litter were taken at 0 and 2 dpi for differential bacteriology. 
     Statistics 
     Shapiro-Wilk test was used for normality testing and a Mann-Whitney rank sum test was conducted as implemented in the software package. Statistical significance was tested using SigmaPlot software. 
     Results 
     Antibody Detection in Serum: 
     All piglets of the CDV group showed positive results in the ELISA (detecting antibodies against PEDV Spike protein) prior to challenge inoculation due to antibody positive colostrum intake, while all animals of the positive and negative control group showed clearly negative results. 
     At 14 dpi all but three piglets in the positive control group seroconverted, while all animals in the vaccine group showed still high amounts of PEDV specific IgG in serum samples. 
     At the end of the study all piglets of the CDV group and of the positive control group showed strongly positive results in the ELISA. None of the animals in the negative control seroconverted during the whole trial. 
     In a further study it was also seen that respective antibody results were likewise achieved when the mother sows were only vaccinated twice via the intranasal route. 
     Bacteriology: 
     Fecal swabs taken at 0 and 2 dpi did not show any pathogenic bacteria. The bacterial flora did not undergo significant changes upon infection. 
     Clinical Signs: 
     Piglets of the positive control group (group 2) clearly showed clinical signs indicative for PEDV over 7 days starting with vomiting 24 hpi followed by diarrhea. 8 of 26 of the piglets had to be euthanized due to severe dehydration and clinical score values over 6 (humane endpoint). First clinical signs indicative for PEDV were detectable at 36 hpi. 
     In total, the clinical signs of the CDV vector vaccinated and PEDV challenged piglets (group 3) were better regarding the general behavior and only 2 of 20 (10%) of the pigs of group 3 had to be euthanized due to severe dehydration and clinical score values over 6 (as compared to 31% of the piglets of group 2). 
     Animals in the negative control stayed healthy during the whole trial. 
     Shedding of Virus 
     A clear difference in virus shedding could be detected between the challenged groups. At 1 dpi all challenged piglets were positive for virus genome in rectal swabs, but animals in the CDV-PEDV vaccinated group showed significantly lower PEDV genome copy numbers (mean CT value 32.79), then in challenge group (mean CT value 26.65). 
     Also, while for the next five days pi, the genome load in rectal swabs of the CDV group was quite similar to the positive control, beginning at 7 dpi the detectable amount of virus genome declined below the cutoff level in piglets protected by the vaccinated sows, while all animals in the positive control group still shed PEDV. 
     No PEDV genome could be detected in swabs of the negative control group. 
     In conclusion, the outcome of the study was that piglets born to sows vaccinated with the CDV_PEDV-Spike recombinant vaccine showed a reduction of clinical signs, as compared to the positive control, and in particular, a great improvement was seen with regard to the mortality/letality of the piglets. Furthermore, virus shedding after the PEDV challenge was significantly reduced. 
     All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the following claims. 
     The following clauses are also disclosed herein:
     1. An expression cassette for insertion between two adjacent essential genes (1; 2) of a Paramyxoviridae virus such that the first gene (1) is located in 3″direction and the second gene (2) is located in 5′ direction of the expression cassette, wherein said expression cassette comprises
       a first nucleotide sequence, wherein said first nucleotide sequence is a nucleotide sequence of interest, and   a second nucleotide sequence flanking the 5′ end of the first nucleotide sequence, wherein said second nucleotide sequence is the 5′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the first gene (1), and   a third nucleotide sequence flanking the 3′ end of the first nucleotide sequence, wherein said third nucleotide sequence comprises or consists of the 3′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2).   
       2. The expression cassette of clause 1, wherein said expression cassette consists of
       said first nucleotide sequence, and   said second nucleotide sequence, and   said third nucleotide sequence, and   a further nucleotide sequence flanking the 5′ end of said second nucleotide sequence or flanking the 3′ end of said third nucleotide sequence, wherein said further nucleotide sequence is an intergenic sequence of a Paramyxoviridae virus.   
       3. The expression cassette of clause 1 or 2, wherein said third nucleotide sequence consists of
       the 3′ non-coding region of a gene selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2), and   a sequence flanking the 5′ end of said 3′ non-coding region, wherein said sequence flanking the 5′ end of said 3′ non-coding region encodes a consensus sequence for initiation or enhancing of translation, and wherein said consensus sequence for initiation or enhancing of translation is optionally a Kozak sequence.   
       4. The expression cassette of any one of clauses 1 to 3, wherein said two adjacent genes (1; 2) of a Paramyxoviridae virus are selected from the group consisting of the essential genes of a Paramyxoviridae virus, and/or
       wherein said essential genes of a Paramyxoviridae virus are
           the N, P, M, F, H and L gene of a Paramyxoviridae virus, or   the N, P, M, F, HN and L gene of a Paramyxoviridae virus, or   the N, P, M, F, G, and L gene of a Paramyxoviridae virus.   
           
       5. The expression cassette of any one of clauses 1 to 4 for insertion between the P gene and the M gene of a Paramyxoviridae virus, wherein
       said group consisting of the essential genes of a Paramyxoviridae virus excluding the first gene (1) is the group consisting of the essential genes of a Paramyxoviridae virus excluding the P gene of a Paramyxoviridae virus, and wherein said gene is optionally selected from the group consisting of the N, M, F, H and L gene of a Paramyxoviridae virus, and   said group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2) is the group consisting of the essential genes of a Paramyxoviridae virus excluding the M gene of a Paramyxoviridae virus, and wherein said gene is optionally selected from the group consisting of the H, P, F, L and N gene of a Paramyxoviridae virus.   
       6. The expression cassette of any one of clauses 1 to 5, wherein
       said second nucleotide sequence is the 5′ non-coding region of a gene selected from the essential genes of a Paramyxoviridae virus located in 3′ direction of the expression cassette, excluding the 5′ non-coding region of the first gene (1), and/or   said third nucleotide sequence comprises or consists of the 3′ non-coding region of an essential gene of a Paramyxoviridae virus located in 5′ direction of the expression cassette, excluding the 3′ non-coding region of the second gene (2).   
       7. The expression cassette of any one of clauses 1 to 6, wherein said first nucleotide sequence is operably linked to the gene start (GS) sequence included in said third nucleotide sequence and/or to the genome promoter of a Paramyxoviridae virus.   8. The expression cassette of any one of clauses 1 to 7, wherein said nucleotide sequences are RNA sequences.   9. A Paramyxoviridae virus vector, comprising the expression cassette of any one of clauses 1 to 8.   10. The expression cassette of any one of clauses 1 to 8 or the Paramyxoviridae virus vector of clause 9, wherein
       said 5′ non-coding region is the 5′ non-coding region of an N gene of a Paramyxoviridae virus, and/or   said 3′ non-coding region is the 3′ non-coding region of an H gene of a Paramyxoviridae virus,   and/or wherein said expression cassette is inserted between a P gene and an M gene of a Paramyxoviridae virus.   
       11. A Paramyxoviridae virus vector, comprising an RNA sequence inserted between two adjacent essential genes (1; 2) of a Paramyxoviridae virus such that the first gene (1) is located in 3′ direction and the second gene (2) is located in 5′ direction of said inserted RNA sequence, and wherein said inserted RNA sequence comprises or consists of
       a first RNA sequence, wherein said first RNA sequence is a nucleotide sequence of interest, and   a second RNA sequence flanking the 5′ end of the first RNA sequence, wherein said second RNA sequence is the 5′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the first gene (1), and   a third RNA sequence flanking the 3′ end of the first RNA sequence, wherein said third RNA sequence comprises or consists of the 3′ non-coding region of a gene, wherein said gene is selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2).   
       12. The Paramyxoviridae virus vector of clause 11, wherein said third RNA sequence consists of
       the 3′ non-coding region of a gene selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2), and   a sequence flanking the 5′ end of said 3′ non-coding region, wherein said sequence flanking the 5′ end of said 3′ non-coding region encodes a consensus sequence for initiation or enhancing of translation, and wherein said consensus sequence for initiation or enhancing of translation is optionally a Kozak sequence.   
       13. The Paramyxoviridae virus vector of clause 11 or 12, further comprising
       a fourth RNA sequence flanking the 5′ end of the second RNA sequence, wherein said fourth RNA sequence is an intergenic sequence of a Paramyxoviridae virus, and/or   a fifth RNA sequence flanking the 3′ end of the fourth RNA sequence, wherein said fifth RNA sequence is an intergenic sequence of a Paramyxoviridae virus.   
       14. The Paramyxoviridae virus vector of any one of clauses 11 to 13, wherein said two adjacent genes (1; 2) of a Paramyxoviridae virus are selected from the group consisting of the essential genes of a Paramyxoviridae virus, and/or
       wherein said essential genes of a Paramyxoviridae virus are
           the N, P, M, F, H and L gene of a Paramyxoviridae virus, or   the N, P, M, F, HN and L gene of a Paramyxoviridae virus, or   the N, P, M, F, G, and L gene of a Paramyxoviridae virus.   
           
       15. The Paramyxoviridae virus vector of any one of clauses 11 to 14, wherein said two adjacent essential genes (1; 2) of a Paramyxoviridae virus are the P gene and the M gene of a Paramyxoviridae virus, and wherein
       said group consisting of the essential genes of a Paramyxoviridae virus excluding the first gene (1) is the group consisting of the essential genes of a Paramyxoviridae virus excluding the P gene of a Paramyxoviridae virus, and wherein said gene is optionally selected from the group consisting of the N, M, F, H and L gene of a Paramyxoviridae virus, and   said group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2) is the group consisting of the essential genes of a Paramyxoviridae virus excluding the M gene of a Paramyxoviridae virus, and wherein said gene is optionally selected from the group consisting of the H, P, F, L and N gene of a Paramyxoviridae virus.   
       16. The Paramyxoviridae virus vector of any one of clauses 11 to 15, wherein
       said second nucleotide sequence is the 5′ non-coding region of a gene selected from the essential genes of a Paramyxoviridae virus located in 3′ direction of the expression cassette, excluding the 5′ non-coding region of the first gene (1), and/or   said third nucleotide sequence comprises or consists of the 3′ non-coding region of an essential gene of a Paramyxoviridae virus located in 5′ direction of the expression cassette, excluding the 3′ non-coding region of the second gene (2).   
       17, The Paramyxoviridae virus vector of any one of clauses 11 to 16, wherein
       said 5′ non-coding region is a 5′ non-coding region of an N gene of a Paramyxoviridae virus, and/or   said 3′ non-coding region is a 3′ non-coding region of an H gene of a Paramyxoviridae virus.   
       18. The Paramyxoviridae virus vector of any one of clauses 11 to 17, wherein
       said first RNA sequence is operably linked to the gene start (GS) sequence included in said third RNA sequence and/or to the genome promoter of a Paramyxoviridae virus.   
       19, The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said Paramyxoviridae virus is a virus of the genus Morbillivirus, and wherein the virus of the genus Morbillivirus is preferably selected from the group consisting of canine distemper virus (CDV), feline morbillivirus (FeMV), and peste-des-petits-ruminants virus (PPRV), and wherein the virus of the genus Morbillivirus is most preferably a canine distemper virus (CDV).   20, The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said Paramyxoviridae virus is a CDV, and wherein said 5′ non-coding region of a gene of a CDV is selected from the group consisting of
       the 5′ non-coding region of an N gene of a CDV, wherein the 5′ non-coding region of an N gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:1,   the 5′ non-coding region of a P gene of a CDV, wherein the 5′ non-coding region of a P gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:2,   the 5′ non-coding region of an M gene of a CDV, wherein the 5′ non-coding region of an M gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:3,   the 5′ non-coding region of an F gene of a CDV, wherein the 5′ non-coding region of an F gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:4,   the 5′ non-coding region of an H gene of a CDV, wherein the 5′ non-coding region of an H gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:5, and   the 5′ non-coding region of an L gene of a CDV, wherein the 5′ non-coding region of an L gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:6.   
       21. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said Paramyxoviridae virus is a CDV, and wherein said 3′ non-coding region of a gene of a CDV is selected from the group consisting of
       the 3′ non-coding region of an H gene of a CDV, wherein the 3′ non-coding region of an H gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:7,   the 3′ non-coding region of an N gene of a CDV, wherein the 3′ non-coding region of an N gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:8,   the 3′ non-coding region of a P gene of a CDV, wherein the 3′ non-coding region of a P gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:9,   the 3′ non-coding region of an M gene of a CDV, wherein the 3′ non-coding region of an M gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:10,   the 3′ non-coding region of an F gene of a CDV, wherein the 3′ non-coding region of an F gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:11, and   the 3′ non-coding region of an L gene of a CDV, wherein the 3′ non-coding region of an L gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:12.   
       22. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said second nucleotide sequence or said second RNA sequence is the 5′ non-coding region of an N gene of a CDV, and wherein said 5′ non-coding region of an N gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:1.   23. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein
       said 3′ non-coding region of a gene selected from the group consisting of the essential genes of a Paramyxoviridae virus excluding the second gene (2) is the 3′ non-coding region of an H gene of a CDV, and wherein said 3′ non-coding region of an H gene of a CDV preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:7, and/or   said sequence flanking the 5′ end of said 3′ non-coding region sequence encodes a Kozak sequence being 5 to 8 nucleotides in length, and wherein the Kozak sequence preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:13.   
       24. The expression cassette of any one of clauses 2 to 8, and 19 to 23 or the Paramyxoviridae virus vector of any one of clauses 9, and 13 to 23, wherein said intergenic sequence of a Paramyxoviridae virus is an intergenic sequence of a CDV, and wherein said intergenic sequence of a CDV preferably consists of or comprises an RNA sequence being at least 66% identical with the sequence of SEQ ID NO:14.   25. The expression cassette or Paramyxoviridae virus vector of any one of the preceding clauses, wherein said nucleotide sequence of interest is a gene of interest or an antigen encoding sequence, and/or wherein said nucleotide sequence of interest is non-naturally occurring and/or recombinant.   26. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said nucleotide sequence of interest is recombinant and/or heterologous and/or exogenous.   27. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said nucleotide sequence of interest encodes an antigen from a disease-causing agent, wherein the disease-causing agent is preferably a disease-causing agent capable of infecting a companion animal, such as a canine or feline and/or any other domestic or wild carnivore, or capable of infecting a food producing animal such as swine or cattle.   28. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein
       the Paramyxoviridae virus is a Paramyxoviridae virus capable of infecting an animal of a first biological family, and   the nucleotide sequence of interest encodes an antigen from a disease-causing agent capable of infecting an animal of said first biological family, and wherein said disease-causing agent is preferably different from said Paramyxoviridae virus,   and wherein said animal of said first biological family is preferably selected from the group consisting of an animal of the family canidae, an animal of the family felidae and an animal of the family suidae, and wherein said animal of said first biological family is most preferably a canine, feline or swine such as a dog, cat or pig.   
       29. The expression cassette or Paramyxoviridae virus vector of clause 28, wherein
       said Paramyxoviridae virus capable of infecting an animal of a first biological family is a CDV and   said disease-causing agent capable of infecting an animal of said first biological family is a Canine Parvovirus (CPV),   or wherein   said Paramyxoviridae virus capable of infecting an animal of a first biological family is a La Piedad Michoacán Mexico virus (LPMV) and   said disease-causing agent capable of infecting an animal of said first biological family is a a swine influenza virus (SwIV) or a porcine epidemic diarrhea virus (PEDV).   
       30, The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said nucleotide sequence of interest encodes an antigen from a canine parvovirus (CPV), feline parvovirus (FPV), swine influenza virus (SwIV) or porcine epidemic diarrhea virus (PEDV).   31. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said nucleotide sequence of interest encodes
       a Protoparvovirus capsid protein, and wherein said Protoparvovirus capsid protein is preferably selected from the group consisting of Carnivore protoparvovirus 1 (CPV or FPV) capsid protein, Primate protoparvovirus 1 capsid protein, Rodent protoparvovirus 1 capsid protein, Rodent protoparvovirus 2 capsid protein, Ungulate parvovirus 1 (PPV) capsid protein; or   an influenza virus envelope protein, wherein said envelope protein is optionally hemagglutinin and/or wherein said influenza virus is optionally selected from the group consisting of influenza A virus, influenza B virus and influenza C virus, and wherein the influenza A virus is preferably selected from the group of the influenza viruses H3N2, H3N1, H1N1, H1N2, H2N1, H2N3 and H911; or   a coronavirus Spike (S) protein, and wherein said coronavirus S protein is preferably selected from the group consisting of Alpaca coronavirus S protein, Alphacoronavirus 1 S protein, Human coronavirus 229E S protein, Human Coronavirus NL63 S protein, Porcine epidemic diarrhea virus (PEDV) S protein, Human coronavirus OC43 S protein, Human coronavirus HKU1 S protein, Murine coronavirus S protein, Severe acute respiratory syndrome-related coronavirus (SARS-CoV) S protein, Middle East respiratory syndrome-related coronavirus (MERS-CoV) S protein and Avian infectious bronchitis virus (IBV) S protein.   
       32. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said nucleotide sequence of interest encodes
       a Canine Parvovirus (CPV) VP2 protein, and wherein said CPV VP2 protein preferably comprises or consists of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35; or   an H3-subtype hemagglutinin (H3), in particular H3 of a swine influenza virus, and wherein said H3 preferably comprises or consists of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:36; or   a porcine epidemic diarrhea virus (PEDV) spike (S) protein, and wherein said PEDV S protein preferably comprises or consists of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:45.   
       33. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said nucleotide sequence of interest encodes
       a Canine Parvovirus (CPV) VP2 protein, and wherein said sequence encoding a CPV VP2 protein preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:15; or   an H3-subtype hemagglutinin (H3), preferably H3 of a swine influenza virus, and wherein said sequence encoding H3 preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:16; or   a porcine epidemic diarrhea virus (PEDV) spike (S) protein, and wherein said sequence encoding a PEDV S protein preferably consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:37 or SEQ ID NO:38.   
       34. The expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, wherein said expression cassette consists of or said Paramyxoviridae virus vector comprises
       a polynucleotide having an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:17 or SEQ ID NO:18; or   a polynucleotide having an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:19 or SEQ ID NO:20; or   a polynucleotide having an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:39 or SEQ ID NO:40.   
       35. The Paramyxoviridae virus vector of any one of the preceding clauses comprising
       an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:21; or   an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:22; or   an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:41.   
       36. The Paramyxoviridae virus vector of any one of clauses 13 to 35, further comprising
       a sixth RNA sequence flanking the 5′ end of the fourth RNA sequence, wherein said sixth RNA sequence consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:23, and/or   a seventh RNA sequence flanking the 3′ end of the fifth RNA sequence, wherein said seventh RNA sequence consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:24.   
       37. A CDV vector comprising a heterologous nucleotide sequence of interest, wherein said heterologous nucleotide sequence of interest encodes a Canine Parvovirus (CPV) VP2 protein.   38. The CDV vector of clause 37, wherein said heterologous nucleotide sequence of interest encoding a CPV VP2 protein consists of or comprises an RNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:15.   39. The CDV vector of clause 37 or 38, wherein said CPV VP2 protein comprises or consists of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35.   40. The CDV vector of any one of clauses 37 to 39, wherein
       said heterologous nucleotide sequence of interest is located between a P gene and an M gene of a CDV; and/or   said heterologous nucleotide sequence of interest is operably linked to a gene start (GS) sequence located in 3′ direction of said heterologous RNA sequence and/or to the genome promoter of a CDV.   
       41. The CDV vector of clause 40, wherein said GS sequence is included in an exogenous 3′ non-coding region of a gene of a CDV, and wherein said exogenous 3′ non-coding region of a gene of a CDV preferably flanks the 3′ end of the heterologous nucleotide sequence of interest, and/or
       wherein said heterologous nucleotide sequence of interest is an RNA sequence of interest.   
       42. A nucleic acid molecule which encodes the expression cassette or the Paramyxoviridae virus vector of any one of the preceding clauses, and wherein said nucleic acid molecule is preferably a DNA molecule.   43. A DNA molecule, in particular the DNA molecule of clause 42, wherein said molecule comprises
       (i) a DNA sequence encoding a polypeptide of interest,   (ii) a DNA sequence flanking the 3′ end of the sequence of (i) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:25,   (iii) a DNA sequence flanking the 5′ end of the sequence of (i) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:26, and   (iv) a DNA sequence flanking the 5′ end of the sequence of (iii) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:27.   
       44. The DNA molecule of clause 43, further comprising
       (v) a DNA sequence flanking the 5′ end of the sequence of (ii) and being at least 66% identical with the sequence of SEQ ID NO:28, and/or   (vi) a DNA sequence flanking the 3′ end of the sequence of (iv) and being at least 66% identical with the sequence of SEQ ID NO:28.   
       45. The DNA molecule of clause 44, further comprising
       (vii) a DNA sequence flanking the 3′ end of the sequence of (v) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:29, and/or   (viii) a DNA sequence flanking the 5′ end of the sequence of (vi) and being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:30.   
       46. The DNA molecule of any one of clauses 42 to 45, wherein the sequence of (i) is
       a DNA sequence encoding a Canine Parvovirus (CPV) VP2 protein, and wherein said sequence is preferably a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:31, or   a DNA sequence encoding an H3-subtype hemagglutinin (H3), preferably H3 of a swine influenza virus, and wherein said sequence is preferably a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:32; or   a DNA sequence encoding a PEDV S protein, and wherein said sequence is preferably a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:42 or SEQ ID NO:43.   
       47. The DNA molecule of any one of clauses 42 to 46, wherein said DNA molecule comprises
       a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:33; or   a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:34; or   a DNA sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:44.   
       48. A mammalian host cell containing the expression cassette or Paramyxoviridae virus vector or DNA acid molecule according to any one of the preceding clauses.   49. The expression cassette or Paramyxoviridae virus vector or nucleic acid molecule according to any one of the preceding clauses for use as a medicament, preferably as a vaccine.   50. A DNA construct comprising a DNA molecule according to any one of clauses 42 to 47.   51. An RNA transcript of the DNA construct of clause 50.   52. A cell transfected with the DNA construct of clause 50.   53. A cell transfected with the RNA transcript of clause 51.   54. A method for the preparation of an infectious Paramyxoviridae virus containing a heterologous gene, in particular for preparing the Paramyxoviridae virus vector of any one of clauses 9 to 41, wherein said method comprises the steps of:
       a. providing a host cell expressing a heterologous RNA polymerase;   b. transfecting the host cell with the DNA construct of clause 50, and wherein the DNA molecule is transcribed by the heterologous RNA polymerase, and   c. isolating the viruses produced by the cells.   
       55. Use of the vector of any one of clauses 9 to 41 or of the cell according to any one of clauses 48, 52 and 53 for the manufacture of an immunogenic composition or a vaccine.   56. An immunogenic composition comprising
       the vector according to any one of clauses 9 to 41, wherein said vector is optionally an infectious and/or attenuated virus or said vector is optionally an attenuated and/or modified live virus, and optionally   a recombinant protein expressed by said vector and/or a virus like particle comprising a plurality of a recombinant protein expressed by said vector, and optionally   a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is preferably suitable for oral, intradermal, intramuscular or intranasal application.   
       57. The immunogenic composition of clause 56, wherein said recombinant protein expressed by the vector is
       a parvovirus VP2 antigen such as CPV VP2 protein or   an influenza virus envelope protein, wherein said envelope protein is optionally hemagglutinin such as H3.   
       58. The immunogenic composition of clause 56 or 57, comprising or consisting of
       the CDV vector of any one of clauses 37 to 41, and wherein said vector is preferably the vector of any one of clauses 19 to 36, and optionally   a polypeptide or recombinant protein comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35 or SEQ ID NO:36, and optionally   a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is preferably suitable for oral, intradermal, intramuscular or intranasal application.   
       59. The immunogenic composition of clause 56 or 57, comprising or consisting of
       the vector of any one of clauses 19 to 36, and wherein said vector is preferably the CDV vector of any one of clauses 37 to 41, and optionally   a recombinant protein expressed by said vector, wherein said recombinant protein comprises or consists of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35 or SEQ ID NO:36, and optionally   a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is preferably suitable for oral, intradermal, intramuscular or intranasal application.   
       60. The immunogenic composition of clause 56, wherein said recombinant protein expressed by said vector is a coronavirus S protein, and wherein said coronavirus S protein is optionally a PEDV S protein.   61. The immunogenic composition of clause 56 or 60, wherein said recombinant protein expressed by said vector is a PEDV S protein comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:45.   62. A vaccine or pharmaceutical composition comprising
       a. the vector according to any one of clauses 9 to 41, and   b. a recombinant protein expressed by said vector and/or a virus like particle comprising a plurality of a recombinant protein expressed by said vector, and   c. a pharmaceutical- or veterinary-acceptable carrier or excipient, preferably said carrier is suitable for oral, intradermal, intramuscular or intranasal application, and   d. optionally said vaccine further comprises an adjuvant.   
       63. The vaccine or pharmaceutical composition according to clause 62, wherein said recombinant protein expressed by the vector is
       a parvovirus VP2 antigen such as CPV VP2 protein or   an influenza virus envelope protein, wherein said envelope protein is optionally hemagglutinin such as H3.   
       64. The vaccine or pharmaceutical composition of clause 62 or 63, comprising or consisting of
       a. the CDV vector of any one of clauses 37 to 41, and wherein said vector is preferably the vector of any one of clauses 19 to 36, and   b. a polypeptide or recombinant protein comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35 or SEQ ID NO:36, and   c. a pharmaceutical- or veterinary-acceptable carrier or excipient, preferably said carrier is suitable for oral, intradermal, intramuscular or intranasal application,   d. and optionally an adjuvant.   
       65. The vaccine or pharmaceutical composition of clause 62 or 63, comprising or consisting of
       a. the CDV vector of any one of clauses 19 to 36, and wherein said vector is preferably the vector of any one of clauses 37 to 41, and   b. a recombinant protein expressed by said vector, wherein said recombinant protein comprises or consists of an amino acid sequence being comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:35 or SEQ ID NO:36, and   c. a pharmaceutical- or veterinary-acceptable carrier or excipient, preferably said carrier is suitable for oral, intradermal, intramuscular or intranasal application,   d. and optionally an adjuvant.   
       66. The vaccine or pharmaceutical composition of clause 62, wherein said recombinant protein expressed by said vector is a coronavirus S protein, and wherein said coronavirus S protein is optionally a PEDV S protein.   67. The vaccine or pharmaceutical composition of clause 62 or 66, wherein said recombinant protein expressed by said vector is a PEDV S protein comprising or consisting of an amino acid sequence being at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical with the sequence of SEQ ID NO:45.   68. The immunogenic composition according to any one of clauses 56 to 61 or the vaccine or pharmaceutical composition according to any one of clauses 62 to 67, wherein said vector is the vector of clause 27.   69. The immunogenic composition according to any one of clauses 56 to 61 or the vaccine or pharmaceutical composition according to any one of clauses 62 to 67, wherein said vector is the vector of clause 28.   70. The immunogenic composition according to any one of clauses 56 to 61 or the vaccine or pharmaceutical composition according to any one of clauses 62 to 67, wherein said vector is the vector of clause 29.   71. A method for the preparation of an immunogenic composition or a vaccine for reducing the incidence or the severity of one or more clinical signs associated with or caused by an infection, comprising the following steps:
       a. infecting a mammalian host cell with the vector according to any one of clauses 9 to 41,   b. cultivating the infected cells under suitable conditions,   c. collecting infected cell cultures,   d. optionally purifying the collected infected cell cultures of step c),   e. optionally mixing said collected infected cell culture with a pharmaceutically acceptable carrier.   
       72. The method according to clause 71, wherein said immunogenic composition or said vaccine reduces, in particular in an animal, the severity of one or more clinical signs associated with or caused by
       an infection with canine distemper virus (CDV) and/or canine parvovirus (CPV) or   an infection with an influenza virus, wherein said influenza virus is optionally selected from the group consisting of influenza A virus, influenza B virus and influenza C virus, and wherein the influenza A virus is preferably selected from the group of the influenza viruses H3N2, H3N1, H1N1, H1N2, H2N1, H2N3 and H911, or   an infection with a coronavirus, wherein said coronavirus is optionally selected from the group consisting of Alpaca coronavirus, Alphacoronavirus 1, Human coronavirus 229E, Human Coronavirus NL63, Porcine epidemic diarrhea virus (PEDV), Human coronavirus OC43, Human coronavirus HKU1, Murine coronavirus, Severe acute respiratory syndrome-related coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV) and Avian infectious bronchitis virus (IBV).   
       73. The immunogenic composition according to any one of clauses 56 to 61 or the vaccine or pharmaceutical composition according to any one of clauses 62 to 67 for use in a method of reducing or preventing the clinical signs or disease caused by an infection with at least one pathogen in an animal or for use in a method of treating or preventing an infection with at least one pathogen in an animal, preferably said animal is a companion animal, such as a canine or feline and/or any other domestic or wild carnivore, or a food producing animal such as swine.   74. The immunogenic composition according to any one of clauses 56 to 61 or the vaccine or pharmaceutical composition according to any one of clauses 62 to 67 for use according to clause 73, wherein said infection with at least one pathogen is
       an infection with CDV and/or CPV or   an infection with swine influenza virus, wherein the swine influenza virus is optionally a subtype H3 influenza virus, and wherein said subtype H3 influenza virus is preferably a swine influenza virus of the subtype H3N2 or H3N1 or   an infection with PEDV.   
       75. The immunogenic composition according to any one of clauses 56 to 61 or the vaccine or pharmaceutical composition according to any one of clauses 62 to 67 for use in a method for
       inducing an immune response against CPV and CDV in an animal, preferably in a canine, or   inducing an immune response against swine influenza virus in a pig, wherein the swine influenza virus is optionally a subtype H3 influenza virus, and wherein said subtype H3 influenza virus is preferably a swine influenza virus of the subtype H3N2 or H3N1, or   inducing an immune response against PEDV in a pig, in particular in a preferably pregnant sow.   
       76. The immunogenic composition according to any one of clauses 56, 60 and 61 or the vaccine or pharmaceutical composition according to any one of clauses 62, 66 and 67 for use in a method of reducing or preventing the clinical signs or disease caused by an infection with a PEDV in a piglet, wherein the piglet is to be suckled by a sow to which the immungenic composition has been adminstered.   77. The immunogenic composition for use according to clause 76, wherein said sow to which the immungenic composition has been administered is a sow to which the immunogenic composition has been administered while said sow has been pregnant, in particular with said piglet.   78. The immunogenic composition according to any one of clauses 56 to 61 or the vaccine or pharmaceutical composition according to any one of clauses 62 to 67 for use according to any of clauses 73 to 77, wherein said immunogenic composition or said vaccine or pharmaceutical composition is to be administered mucosally, preferably intranasally.   79. The immunogenic composition according to any one of clauses 56 to 61 or the vaccine or pharmaceutical composition according to any one of clauses 62 to 67 for use according to any one of clauses 75 to 77, wherein said immunogenic composition or said vaccine or pharmaceutical composition is to be administered mucosally, preferably intranasally, to said sow.   80. A method of immunizing an animal such as a companion animal, such as a canine or feline and/or any other domestic or wild carnivore, or a food producing animal including swine against a clinical disease caused by at least one pathogen in said animal, said method comprising the step of administering to the animal the immunogenic composition according to any one of clauses 56 to 61 or the vaccine or pharmaceutical composition according to any one of clauses 62 to 67, wherein said immunogenic composition or vaccine fails to cause clinical signs of infection but is capable of inducing an immune response that immunizes the animal against pathogenic forms of said at least one pathogen.   81. The method of clause 80,
       wherein said at least one pathogen is CDV or CPV or SwIV or PEDV, or   wherein said at least one pathogen is CDV and CPV.   
       82. A method for inducing the production of antibodies specific for PEDV in a sow, wherein said method comprises administering the immunogenic composition according to any one of clauses 56, 60 and 61 or the vaccine or pharmaceutical composition according to any one of clauses 62, 66 and 67 to said sow.   83. A method of reducing or preventing the clinical signs or disease caused by an infection with a PEDV in a piglet, wherein said method comprises
       administering the immunogenic composition according to any one of clauses 56, 60, and 61 or the vaccine or pharmaceutical composition according to any one of clauses 62, 66 and 67 to a sow, and   allowing said piglet to be suckled by said sow.   
       84. The method of clause 83, wherein said sow is a sow being pregnant, in particular with said pig.   85. The method of clause 83 or 84, comprising the steps of
       administering the immunogenic composition according to any one of clauses 56, 60, and 61 or the vaccine or pharmaceutical composition according to any one of clauses 62, 66 and 67 to a sow being pregnant with said piglet,   allowing said sow to give birth to said piglet, and   allowing said piglet to be suckled by said sow.   
       86. The method of any one of clauses 82 to 85, wherein said immunogenic composition or said vaccine or pharmaceutical composition is administered mucosally, preferably intranasally, to said sow.   87, A kit for inducing an immune response against at least one pathogen in an animal or for vaccinating an animal, preferably a companion animal, such as a canine or feline and/or any other domestic or wild carnivore, or food producing animal such as swine or cattle, against a disease associated with and/or reducing the incidence or the severity of one or more clinical signs associated with or caused by at least one pathogen in an animal, comprising:
       a) a syringe or a dispenser capable of administering a vaccine to said animal; and   b) the immunogenic composition according to any one of clauses 56 to 61 or the vaccine according to any one of clauses 62 to 67, and   c) optionally an instruction leaflet,   and wherein said at least one pathogen is preferably CDV and/or CPV   or wherein said at least one pathogen is optionally SwIV or PEDV.   
       88, The method of clause 71 or 72, the immunogenic composition or the vaccine or pharmaceutical composition for use according to any one of clauses 73 to 79, the method according to any one of clauses 80 to 86 or the kit according to clause 87, wherein said immunogenic composition is the immunogenic composition of clause 68, and wherein said at least one pathogen is said disease-causing agent of which the antigen encoded by the nucleotide sequence of interest is from.   89, The method of clause 71 or 72, the immunogenic composition or the vaccine or pharmaceutical composition for use according to any one of clauses 73 to 79, the method according to any one of clauses 80 to 86 or the kit according to clause 87, wherein said immunogenic composition is the immunogenic composition of clause 69, and wherein said at least one pathogen are said Paramyxoviridae virus and said disease-causing agent of which the antigen encoded by the nucleotide sequence of interest is from.   90. The method of clause 71 or 72, the immunogenic composition or the vaccine or pharmaceutical composition for use according to any one of clauses 73 to 79, the method according to any one of clauses 80 to 86 or the kit according to clause 87, wherein said immunogenic composition is the immunogenic composition of clause 70, and wherein said at least one pathogen are said Paramyxoviridae virus and said disease-causing agent of which the antigen encoded by the nucleotide sequence of interest is from.   91. The method of clause 71 or 72, the immunogenic composition or the vaccine or pharmaceutical composition for use according to any one of clauses 73 to 79, the method according to any one of clauses 80 to 86 or the kit according to clause 87, wherein said immunogenic composition is the immunogenic composition of clause 70, and wherein said at least one pathogen are CDV and CPV.   92. The method of any one of clauses 72, 80, 81, and 88 to 91, wherein said animal is a canine, and wherein said canine is preferably a dog.   93, The method of any one of clauses 72, 80, 81, and 88 to 91, wherein said animal is a feline, and wherein said feline is preferably a cat.   94. The immunogenic composition or the vaccine or pharmaceutical composition for use according to any one of clauses 73 to 75, and 88 to 91, wherein said animal is a canine, and wherein said canine is preferably a dog.   95. The immunogenic composition or the vaccine or pharmaceutical composition for use according to any one of clauses 73 to 75, and 88 to 91, wherein said animal is a feline, and wherein said feline is preferably a cat.   96. The kit according to any one of clauses 87, and 88 to 91, wherein said animal is a canine, and wherein said canine is preferably a dog.   97, The kit according to any one of clauses 87, and 88 to 91, wherein said animal is a feline, and wherein said feline is preferably a cat.   

     REFERENCES 
     The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
     1. Parks C L, Wang H P, Kovacs G R, Vasilakis N, Kowalski J, Nowak R M, Lerch R A, Walpita P, Sidhu M S, Udem S A. 2002. Expression of a foreign gene by recombinant canine distemper virus recovered from cloned DNAs. Virus Res; 83(1-2):131-47.   2. von Messling V, Milosevic D, Devaux P, Cattaneo R. 2004. Canine distemper virus and measles virus fusion glycoprotein trimers: partial membrane-proximal ectodomain cleavage enhances function. J Virol. 78(15):7894-903.   3. Wang X, Feng N, Ge J, Shuai L, Peng L, Gao Y, Yang S, Xia X, Bu Z. 2012 Recombinant canine distemper virus serves as bivalent live vaccine against rabies and canine distemper. Vaccine 30(34):5067-72. doi: 10.1016/j.vaccine.2012.06.001. Epub 2012 Jun. 12.   4. Glover S, Anderson C, Piontkowski M, Terry N (2012) Canine Parvovirus (CPV) type 2b vaccine protect puppies with maternal antibodies to CPV when challenged with virulent CPV 2 C virus. International Journal of Applied Research in Veterinary Medicine 10: 217-224   5. Taguchi M, Namikawa K, Maruo T, Orito K, Lynch J, Sahara H. Antibody titers for canine parvovirus type-2, canine distemper virus, and canine adenovirus type-1 in adult household dogs. The Canadian Veterinary Journal. 2011; 52(9):983-986.